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SUMMARY
The work described in this thesis involved investigations 
into the effect of ageing on the physiology and 
pharmacology of the sympathetic nervous system.
Noradrenaline is the principal neurotransmitter of the 
peripheral sympathetic nervous system. It is found in 
increased concentration in the plasma of elderly people. 
The reasons for this increase could be: [1] An increase in 
the spillover of noradrenaline from the nerve terminal,
[2] A reduction in clearance of noradrenaline from the 
plasma, and [3] a combination of both.
The rates of noradrenaline release into, and clearance 
from the circulation were measured in two groups of young 
and elderly volunteers. The resting noradrenaline 
concentrations were higher in the elderly subjects. There 
was no change in the rate of clearance of noradrenaline 
between the groups but the elderly had a higher rate of 
noradrenaline spillover into the circulation.
The activity of the cardiac beta-l-adrenoceptor reduces 
with age. There was no corresponding information 
concerning the activity of the alpha-l-adrenoceptor. The 
second study described in this thesis examined the 
responses of human isolated arteries to noradrenaline.
This provided evidence of the sensitivity of the alpha-l- 
adrenoceptor free from the complicating influence of the
16
baroreceptors. There was no change in the sensitivity of 
this receptor across a wide age range.
Prazosin is an alpha-l-adrenoceptor antagonist. It has 
been used in the treatment of hypertension, heart failure 
and prostatism. The third study examined the pharmaco­
kinetics of prazosin in two groups of young and elderly 
volunteers. Prazosin was administered intravenously and 
orally on two separate days. By this means, a measure of 
the drug bioavailability and clearance may be measured.
In the elderly, there was no change in the rate of 
clearance of prazosin but there was a reduction in 
bioavailability.
The fourth study reported in this thesis concerned a 
combined examination of the pharmacokinetics and pharmaco­
dynamics of three antihypertensive drugs: Trimazosin, an
alpha-l-adrenoceptor antagonist; acebutolol, a beta-l- 
adrenoceptor antagonist; and tolmesoxide, a non-specific 
vasodilator.
This study not only provided information about the 
relative effect of age on the clearance of these drugs but 
also on the effect of age on the sensitivity to the drugs 
(as measured by fall in systolic blood pressure per unit 
of plasma drug concentration). There was an increased 
effect of trimazosin with increasing age. This was due to 
a reduction in drug clearance. The sensitivity of the 
alpha-l-adrenoceptor remained unchanged. There was a
17
reduced effect of acebutolol with increasing age. This
was due to an decrease in the sensitivity of the 
beta-l-adrenoceptor, the drug clearance remaining 
unchanged. There was no change in the sensitivity or
clearance of tolmesoxide with age.
The increase in the plasma concentration of noradrenaline 
and the lack of change in the sensitivity of the alpha-l- 
adrenoceptor provides evidence for the suggestion that 
alpha-l-adrenoceptor antagonists might be useful in the 
treatment of hypertension in the elderly. Prazosin is 
limited by a short duration of action and by a first dose 
hypotensive effect. Doxazosin, which is chemically 
related to prazosin, has a longer half life, and the 
potential for once daily dosing.
The last study in this thesis describes the effect of 
doxazosin on elderly hypertensive patients. Doxazosin 
produced statistically significant, but modest, falls in 
diastolic pressure 24 hours post dose. There was no 
change in systolic pressure.
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CHAPTER 1
BACKGROUND AND SCOPE OF THESIS
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BACKGROUND AND SCOPE OF THESIS.
Old age is not synonymous with ill health. There are 
alterations in physiology, but many of the changes seen 
are of no clinical significance; for example greying hair. 
Other changes can be less benign. Baroreceptor function 
has been shown to decline with age (1). This can result in 
postural hypotension, which in one series, was 
demonstrated in 24% of subjects over the age of 64 (2). 
This diminished ability to respond to postural stress 
contributes to the increased risk of falls seen in the 
elderly, particularly with the onset of disease (3).
The changes that occur with ageing are not just important 
for physiology and pathology, but also pharmacology. Old 
age is associated with changes in drug distribution and 
metabolism as well as drug activity. The importance of 
these changes is illustrated by the increased risk from 
adverse drug reactions (ADRs) experienced by the elderly 
(4).
1.1 PROBLEMS WITH DRUG THERAPY IN THE ELDERLY
There is ample evidence for the increased incidence of 
ADRs in elderly patients (5,6,7,8). In one survey in the 
U.K. as many as 12% of admissions to geriatric medical 
units were recorded as being partly or wholly due to 
adverse drug reactions (9). Most of the severe ADRs are
20
due to commonly prescribed drugs (10).
Not all drugs have an increased risk of ADRs with age.
Skin reactions to drugs do not appear to increase with age 
(11). Occasionally an ADR becomes less common with age, 
as with acute dystonic reactions due to phenothiazines and 
butyrophenones (12), perhaps because there is an age 
related decline in the dopamine levels in the basal 
ganglia.
The causes of the age-related increase in ADRs are 
complex. There is an age-related increase in the number 
of drug prescriptions given to inpatients (9,8,13). This 
reflects in part the necessities imposed by multiple 
pathology which is often seen in the elderly. There is a 
strong correlation between the number of drugs prescribed 
and the risk of an ADR. In one study (13), the risk 
increased from 5% with 1 drug, to 100% if 10 drugs are 
prescribed. The increased number of prescriptions will 
also increase the risk of adverse drug interactions.
These are not particularly common, but they can be serious 
(14) .
Not surprisingly, increasing dose has been shown to be 
related to the incidence of ADRs; e.g. unwanted sedation 
due to flurazepam in the elderly increases from 1.3% at a 
dose of 15 mg/day to 12.3% with a dose of 30 mg/day (15).
Poor drug compliance in the elderly is often blamed for 
ADRs. Compliance is difficult to measure but studies have
21
shown that up to 75% of drugs are not taken correctly 
(16). Interestingly, compliance is probably no worse in 
the young than the old (17,18). Poor compliance usually 
results in the patient failing to take a drug, which may 
help prevent ADRs.
The elderly frequently demonstrate changes in the 
disposition and clearance of drugs (Review: 4). 
Bioavailability (the proportion of an orally administered 
drug that enters the systemic circulation) is almost never 
measured in pharmacokinetic studies and evidence for any 
changes in the elderly is scarce. Pre-systemic 
elimination (first pass metabolism) has been studied in 
the elderly but with conflicting results. Propranolol was 
shown to have reduced pre-systemic elimination in the 
elderly in one study (19) but not in another (2 0). The 
main difference between these two studies was that the 
first involved elderly patients who were suffering from 
chronic disease and the second, normal volunteers. The 
influence of disease is also seen on the binding of drugs 
to protein. The plasma concentration of albumin in the 
elderly tends to decrease with disease (21), and as a 
result the binding of drugs to albumin, e.g. diazepam, 
decreases in the elderly sick (22) . This increases the 
concentration of the free active drug and, as a result, 
the incidence of unwanted sedation.
Once a drug has been absorbed, it will be distributed 
throughout the body in a pattern mainly determined by its 
physico-chemical properties. Ageing is accompanied by
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substantial changes in body composition. There is a 
decrease in lean body mass and body weight with an 
accompanying increase in body fat (23). Thus for 
fat-soluble drugs such as diazepam, the volume of 
distribution increases with age (24) and for water soluble 
drugs such as the model drug antipyrine, there is a 
decrease (25). The main importance of these changes is 
that there is tendency to prolong the elimination half 
life of fat soluble drugs (e.g. diazepam) which may 
prolong effect.
Drug metabolism may also be reduced with age, probably 
related to the reduction in blood flow and size of the 
liver (4). Any reduction in drug metabolism with age is 
unlikely to have great clinical importance because the 
changes are generally of small magnitude, and 
inter-subject variability may be far more important.
Vestal et al (26) demonstrated that there was a 600% 
variability between subjects in hepatic antipyrine 
clearance, while age had only a 3% effect.
Renal excretion of drugs is frequently reduced in the 
elderly (4); e.g. streptomycin (27), cimetidine (28) and 
digoxin (29). However, atenolol also undergoes renal 
elimination and this appears to be unchanged with age 
(30) .
Once a drug has been absorbed and distributed throughout 
the body it reaches its site of action: the drug receptor. 
These are macromolecular complexes found in many sites in
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the cell, including mitochondriae, lysosomes and cell 
membranes (31). Pharmacological effect is produced by the 
combination of the drug and the receptor. Drugs are said 
to possess affinity and intrinsic activity in relation to 
their receptors. Affinity is defined as the efficiency 
with which the drug binds to its receptor, and intrinsic 
activity as its power to generate a stimulus. A drug 
which has both affinity and intrinsic activity is termed 
an agonist, and one which has only affinity but no 
intrinsic activity, an antagonist.
Drug receptor interactions may be affected by age (Review: 
32). Studies on the changes in receptor activity and age 
are difficult to design in humans. There may be changes 
in the absorption, distribution and excretion of the drug 
which can modify response. There appears to be increased 
sensitivity with age, e.g. nitrazepam (33) , and warfarin
(34). Most of experimental work on drug sensitivity and 
age has concerned autonomic nervous system receptors. 
Exercise-induced tachycardia is inversely related to age
(35). This may be due to reduced activity of the cardiac 
beta-l-adrenoceptor but the interpretation of the results 
of the study is complicated by the reduction in 
baroreceptor reflexes seen in the elderly (1). In 
contrast the beta-2-adrenoceptor does not seem to change 
with age (3 6).
The studies described in this thesis were designed to 
examine the effect of age on aspects of the physiology and 
pharmacology of the peripheral sympathetic nervous system.
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The thesis is first concerned with the changes seen in the 
disposition of the neurotransmitter, noradrenaline, and on 
the sensitivity of the post-synaptic alpha-l-adrenoceptor. 
The therapeutic implications of these changes are then 
explored with particular reference to the treatment of 
hypertension in the elderly.
1.2 NORADRENALINE DISPOSITION IN THE ELDERLY.
The first study describes an attempt to identify the 
reason for the increased plasma concentration of 
noradrenaline seen in the elderly (37).
Noradrenaline is the principal neurotransmitter of 
post-ganglionic sympathetic nerves (38). It is 
synthesised in the neurone from tyrosine and then stored 
in vesicles in the terminal axon. The contents of the 
vesicles are discharged into the synaptic cleft by a 
calcium dependent exocytosis which is activated by 
neuronal action potentials. Noradrenaline then combines 
with adrenergic receptors which are present both on the 
pre-synaptic and post-synaptic membranes. Following 
release most of the noradrenaline is recovered by the 
neurone through a reuptake process (39). Approximately 
20% of the released noradrenaline escapes from the 
synaptic cleft and a proportion of this fraction enters 
the circulating plasma (Figure 1).
The concentration of noradrenaline in the plasma may not
25
SYMPATHETIC 
NERVE TERMINAL
Tyrosine
NA
MAO
NA
NA
Spillover to 
plasma
C*T
COMT EFFECTOR
CELL
Figure 1.
Noradrenaline (NA) is produced from tyrosine, is then 
stored in vesicles and released into the synaptic cleft.
It undergoes reuptake into the nerve terminal whete it is 
either oxidised by monoamine-oxidase (MAO) or is taken up 
once more by the vesicles. Some NA may also be taken into 
the effector cell where it undergoes metabolism by 
catechol-O-methyl transferase (COMT). The remainder of 
the NA escapes from the synaptic cleft and a proportion of 
this will reach the plasma.
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reflect accurately sympathetic nervous activity. Plasma 
noradrenaline concentration is not a static measurement as 
it reflects a balance between release into, and clearance 
from the circulation. Although noradrenaline enters the 
circulation effectively from one source - the sympathetic 
nerve terminals - its clearance is more complex. Most of 
the released noradrenaline undergoes reuptake into the 
sympathetic neurones. Once regained by the neurone the 
noradrenaline is either stored once more in the vesicles 
or metabolised by cytoplasmic mono-amine oxidase (MAO).
The noradrenaline which is not removed by the 
post-ganglionic sympathetic nerves may be metabolised by 
catechol-O-methyl transferase (COMT). Uptake may also 
occur into non-neuronal tissue such as muscle but this 
appears not to be an important pathway in humans (40,41).
It is therefore important when considering sympathetic 
activity to measure not only the plasma noradrenaline 
concentration but the rates of release and clearance of 
noradrenaline into and from the circulation.
Plasma noradrenaline concentration has been examined in 
essential hypertension (Review: 42). It became apparent 
that plasma noradrenaline not only increases in some 
hypertensive patients - usually young, newly diagnosed 
cases - but also increased independently with age (37).
The incidence of systolic hypertension also increases with 
age (43) and this raises the question of a relationship 
between the blood pressure and the increased plasma 
noradrenaline concentration found in the elderly (44).
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The elderly also have a greater sympathetic response to 
stress. With isometric exercise and cold pressor testing 
there is an approximate doubling of the rise in plasma 
noradrenaline and blood pressure between the 2nd and 6th 
decades (45). Under mental stress there is an increase in 
plasma noradrenaline in the elderly but not in the young 
(46) .
The site of blood sampling for assessing noradrenaline 
kinetics has to be considered carefully. Sympathetic 
nerve activity and release of noradrenaline is not 
uniform, but may vary considerably between organs (47). 
There may also be changes in the secretion of 
noradrenaline from individual organs without any overall 
change in the peripheral noradrenaline concentration (48). 
The left atrium or pulmonary artery are probably the 
nearest to ideal sites to sample plasma for accurate 
estimation of whole body noradrenaline kinetics, however, 
such sites are too invasive for studies on elderly 
volunteers. Noradrenaline kinetics calculated from 
antecubital venous blood are influenced by local release 
and clearance in the tissues of the forearm (47) but this 
site is easily accessible and is highly acceptable to the 
volunteer subjects.
1.3 AGE AND THE RESPONSE OF HUMAN ISOLATED ARTERIES
This series of experiments involved an examination of 
arteries harvested from patients of a wide age range who
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were undergoing abdominal surgery. I was able to quantify 
the contractile responses of these arteries to 
noradrenaline.
Catecholamines are responsible for the regulation of a 
large variety of endocrine and cardiovascular functions. 
They have influence on plasma glucose, renin and potassium 
concentrations as well as on heart rate and blood 
pressure. The principal catecholamines, adrenaline and 
noradrenaline initiate these actions by combining with 
discrete sites located on the plasma cell membrane: the 
adrenoceptors. These receptors also bind agonist, partial 
agonist and antagonist drugs. An agonist is capable of 
producing a maximum response, while a partial agonist 
causes a response that is qualitatively similar but of a 
lesser magnitude. An antagonist, when in combination with 
the receptor, has no effect other than preventing the 
effect of agonists.
Ahlquist (49) was the first to divide adrenergic receptors 
into alpha and beta. The alpha-adrenoreceptor was 
responsible for vasoconstriction and the beta-adrenoceptor 
for the production of cardiac acceleration. It is now 
recognised that the alpha-adrenoceptors are subdivided 
into alpha-1 and alpha-2 and the beta-adrenoceptors into 
beta-1 and beta-2 (Table 1). These receptors may be found 
at a sympathetic nerve terminal, either on the 
pre-synaptic or post-synaptic membrane or may be found at 
sites distant from innervation, e.g. platelets and 
lymphocytes.
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ARTERIOLES
coronary alpha
beta-2
constriction
dilatation
skin alpha constriction
mucosa alpha constriction
skeletal muscle alpha
beta-2
constriction
dilatation
cerebral alpha constriction
abdominal vicera alpha
beta-2
constriction
dilatation
renal alpha-1
beta-1
beta-2
constriction
dilatation
dilatation
VEINS
systemic alpha-1
beta-2
constriction
dilatation
INTESTINE
motility alpha-1
beta-1
beta-2
decrease
decrease
decrease
EYE
iris alpha-1 contraction
ciliary muscle beta relaxation
PRESYNAPTIC SYMPATHETIC NERVE TERMINAL
alpha-2 decreased release of neurotransmitter
beta increased release of neurotransmitter
TABLE 1: Classification of adrenergic receptors.
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At rest, the major mechanism determining peripheral 
vascular resistance is the tone of the smooth muscle 
cells, generated as a result of intravascular pressure 
(50). The influence of the sympathetic nervous system via 
the vasoconstrictor alpha-l-adrenoceptor is present, but 
is not dominant. However, during physical activity or 
stress other influences become predominant, including the 
alpha-l-adrenoceptor, vasopressin and angiotensin.
Increasing age and disease have been shown to affect the 
activity of the sympathetic nervous system. There is 
almost universal agreement that the effect of cardiac 
beta-l-adrenoceptor stimulation is diminished (Reviews: 
51,52). There is diminished cardiac acceleration in 
elderly subjects following intravenous administration of 
the beta-adrenoceptor agonist, isoprenaline.
The number and activity of adrenoceptors are regulated 
under conditions of acute or chronic over and 
under-stimulation (53). Tissues which are denervated 
become supersensitive to adrenergic agonists due to an 
increased number and activity of the adrenoceptors. 
Similarly, tissues which are exposed to increased 
concentrations of adrenergic agonists may demonstrate 
'down regulation' of the adrenoceptors. In the elderly 
there is an increase in the concentration of noradrenaline 
in the plasma (37). It is attractive to explain the 
diminished response of the cardiac beta-l-adrenoceptor in 
the elderly by 'down-regulation' due to increased exposure
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to circulating noradrenaline, although there is no strong 
evidence to support this theory.
1.4 PRAZOSIN DISTRIBUTION AND AGE
Prazosin is a short acting alpha-l-adrenoceptor 
antagonist. It has limited use in the treatment of 
hypertension. This study investigated the differences in 
prazosin distribution between two groups of young and old 
volunteers.
Very few pharmacokinetic studies attempt to measure the 
oral bioavailability of drugs. To achieve this the drug 
has to be given on two separate occasions by the oral and 
the intravenous routes. The calculations are made on the 
assumption that a drug given by the intravenous route will 
have 100% bioavailability. The use of the intravenous 
method of administration has another advantage; the 
accurate calculation of drug clearance, which is not 
possible with oral dosing.
This study involved the administration of prazosin by the 
oral and intravenous routes and measured the 
bioavailability, distribution and clearance of prazosin in 
the two groups of volunteers. An attempt was also made to 
compare the hypotensive effect of prazosin in these 
subj ects.
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1.5 EFFECT OF AGE ON THE METABOLISM AND EFFECT OF 
TRIMAZOSIN, ACEBUTOLOL AND TOLMESOXIDE.
This study represents a more complex examination of the 
age associated changes in pharmacokinetics and dynamics.
It involved measurement of the effect and plasma 
concentrations of three different hypotensive drugs.
Using a computer program it is possible to integrate data 
from plasma drug concentrations with drug effect (in this 
case: the drop in systolic blood pressure). It is then 
possible to produce a measure of concentration-effect; 
i.e. the fall in blood pressure produced by 1 ng/ml plasma 
drug concentration (54) .
This study provided another refinement in technique over 
that used in the previous examination of prazosin 
kinetics; a range of volunteers was used that provided a 
continuous spectrum of age, rather than two discontinuous 
groups of young and elderly. This allowed for the use of 
regression analysis of age against drug effect or 
clearance, which proved to be a more sensitive measure of 
change.
It was therefore possible not only to comment on the age 
related changes in drug kinetics but also on the changes 
in receptor sensitivity to these drugs. This provided 
more evidence on the effect of ageing on the alpha-1 and 
beta-1 adrenoceptors as well as on the non-adrenergic 
receptor which produces vascular relaxation with 
tolmesoxide.
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1.6 TREATMENT OF THE ELDERLY HYPERTENSIVE PATIENT WITH 
DOXAZOSIN
This clinical study into the treatment of hypertension in 
the elderly was designed to test a hypothesis which arose 
from the results of the experiments on noradrenaline 
disposition and alpha-l-adrenergic sensitivity.
Cardiovascular disease is the single largest cause of 
morbidity and mortality in the elderly. The Framingham 
study has identified hypertension as the dominant risk 
factor for arterial disease (43) . In 'developed' 
societies, the incidence of hypertension increases with 
age. Between the ages of 85 and 94 years the incidence of 
hypertension in males is 38% and in females 48% (43) . The 
European study into the treatment of hypertension (EWHE) 
in the elderly demonstrated a reduction in cardiovascular 
deaths with treatment at least up to the age of 8 0 (55).
The choice of antihypertensive drugs is now considerable 
and most have been shown to be effective in the elderly. 
The European study used a thiazide diuretic with or 
without methyldopa. Beta-adrenoceptor antagonists have 
been shown to be useful (56) despite the theoretical 
objections of reduced beta-l-adrenoceptor activity with 
increasing age. Experience with the more recent drugs 
such as angiotensin converting enzyme inhibitors is more 
limited but they appear to be effective and well tolerated 
by the elderly (57).
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Increasing age is associated with an increase in the 
plasma concentration of noradrenaline (Chapter 2) but 
there appears to be no change in the sensitivity of the 
alpha-l-adrenoceptor (Chapters 3,5). Hypertension in the 
elderly is associated with high peripheral resistance and 
low cardiac output (58) which is quite unlike hypertension 
in the young in whom, especially in the early stages, 
there is a high resting cardiac output. These factors 
taken together have led to the suggestion that vasodilator 
drugs are the logical choice for the elderly hypertensive 
- particularly calcium antagonists (59) . However, the 
combination of high circulating noradrenaline levels 
together with unchanged vasoconstrictor 
alpha-l-adrenoceptor activity suggests the use of 
alpha-l-adrenoceptor antagonists in the elderly 
hypertensive patient.
This study used a double blind cross over design with 
doxazosin against placebo, with three months on each 
treatment. At the end of the study plasma drug 
concentrations were measured over a 24 hour period, giving 
an indication of the elimination half life of this drug in 
the elderly.
The results of this study give an indication of the 
usefulness of once daily doxazosin therapy in the 
treatment of the elderly hypertensive patient.
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CHAPTER 2
THE EFFECT OF AGE ON THE RELEASE AND CLEARANCE OF
NORADRENALINE
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THE EFFECT OF AGE ON THE RELEASE AND CLEARANCE OF
NORADRENALINE.
2.1 INTRODUCTION
The increased plasma noradrenaline concentration found in 
the elderly could be due to an increase in spillover from 
the nerve terminals, a reduction in clearance from the 
plasma, or both. This study was designed to investigate 
the influence of age on noradrenaline release into and 
clearance from plasma taken from the antecubital vein.
2.2 METHODS
Measurement of noradrenaline release and clearance 
The method of assessing noradrenaline release and 
clearance in this study involves the intravenous infusion 
of low concentrations of noradrenaline. The rate of 
noradrenaline infusion is intended to cause minimal or no 
change in blood pressure or heart rate. The infusion is 
continued until a constant plasma concentration of 
noradrenaline is achieved.
Noradrenaline clearance from plasma is then calculated 
using the relationship:-
Infusion rate
C1 =  ---------------------------
Css - Cb
Cl = clearance, Css = mean steady state noradrenaline
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concentration and Cb = mean basal (pre-infusion) supine 
nordrenaline concentration (60).
The endogenous rate of noradrenaline release (Rn) into the
. —1circulation (nmol.min ) under steady state conditions 
prior to the infusion is calculated by the formula:-
Rn = Cl x Cb
Volunteer selection
Eight young and eight elderly male volunteers were 
recruited. The young consisted of hospital laboratory 
technicians who had not taken part in similar studies 
before. The median age of the young group was 29 years 
with a range of 21-3 6 years. The elderly volunteers were 
recruited with the aid of the age-sex register of a local 
general practitioner. The median age was 7 0 years with a 
range of 65-78 years.
Both groups of volunteers were made familiar with the 
clinical laboratory, the equipment and experimental 
techniques before the study days. In particular the 
elderly subjects visited the hospital and clinical 
laboratory prior to the study. None of the subjects had 
experienced any previous serious illnesses and none were 
taking any drugs. All were living independently at home. 
All subjects had a physical examination prior to the study 
day and all had normal haematological and biochemical 
indices as well as a normal electrocardiogram.
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Study protocol
At approximately 083 0hrs on the study day, a venous 
cannula was inserted in each forearm and filled with 
saline containing 20 units.ml  ^ of heparin. An arm cuff 
was fitted for blood pressure recording using an automated 
sphygmomanometer (Bosomat). The subjects then rested 
quietly for 2 0 minutes after which time they stood for 5 
minutes on three separate occasions during the next 3 0 
minutes. At the end of each 5 minute period blood was 
drawn via one of the intravenous cannulae for 
catecholamine analysis. Pulse and blood pressure 
recordings were made frequently. The subjects then rested 
for a further 2 0 minutes and thereafter three further 
samples were withdrawn for catecholamine analysis. Blood 
pressure and heart rate were measured simultaneously.
Noradrenaline (Levophed, Winthrop Laboratories) was then 
infused into the second intravenous cannula using a 
constant rate pump (Braun). The subjects remained supine 
throughout. Noradrenaline solutions were made up in 
normal saline and to prevent oxidation 1% ascorbic acid 
was added, and both the syringe and connecting tubing were 
protected from the light. The infusion solutions were 
analysed at the end of the study for catecholamine 
concentration.
Noradrenaline was infused at increasing rates of 0.01,
— I . — 10.02 and 0.03 microgram.kg .min for 10 minutes each.
At the eighth and tenth minute of each infusion rate, 
blood samples were withdrawn for noradrenaline analysis.
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Noradrenaline was then infused at
0.06 microgram,kg .min  ^ for 180 minutes, blood samples 
being taken at 3 0 minute intervals. Blood pressure 
measurements were carefully recorded throughout the 
infusion period to detect any excessive rise which would 
have resulted in the study not proceeding to the 
administration of a higher noradrenaline concentration.
Blood for noradrenaline analysis was drawn into chilled 
plastic syringes, transferred to cold heparinised tubes 
and immediately centrifuged at 4°C. The plasma was 
separated and then stored at -20°C until analysed.
Analysis of noradrenaline in plasma
In the adrenal medulla, in chromaffin cells and in some 
neurones in the central nervous system,
phenylethanolamine-N-methyl transferase (PNMT) converts 
noradrenaline to adrenaline using a methyl group derived 
from S-adenosyl-methionine (SAME). This biochemical 
pathway has been used to develop an assay for 
noradrenaline (61). The assay for plasma noradrenaline in 
this study uses SAME with a radiolabelled methyl group. 
Partially purified PNMT obtained from bovine adrenal 
glands is used to transfer this tritiated methyl group to 
the noradrenaline, forming tritiated-adrenaline. This 
tritiated-adrenaline is then separated from the labelled 
precursor by absorption onto alumina and then extraction 
into perchloric acid. The concentration of tritiated- 
adrenaline is then measured by liquid scintillation and 
this result is proportional to the amount of noradrenaline
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originally present. The assay is highly sensitive and 
specific for noradrenaline. None of the naturally 
occuring catecholamines or their metabolites either 
interfere with or are detected by the assay.
Statistical analysis
Results are expressed as the median and range for the 
group. Values for young and old are compared by 
two-tailed Wilcoxon rank sum test. Noradrenaline 
clearance at the four infusion rates was compared by 
Friedman two-way analysis of variance. The possibility of 
a relationship between the rate of noradrenaline entry 
into the circulation and blood pressure for all sixteen 
subjects was investigated using a computer program for 
generalized linear interactive modelling (62).
2.3 RESULTS
The demographic data and baseline blood pressure 
recordings for the volunteers are shown in Table 2. The 
systolic and diastolic pressures for the elderly were 
signficantly higher than for the young in both supine and 
standing positions. The basal heart rate did not differ 
between young and old in either position. In both groups 
the blood pressure increased on moving from the supine to 
the standing position by the same proportion, (systolic 
pressure increased by a median of 4.6% in the elderly and 
4.3% in the young; diastolic pressure increased by a 
median of 9.0% in the elderly and 9.2% in the young).
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SYSTOLIC BP 
(mmHg) 
(median 
range)
DIASTOLIC BP 
(mmHg) 
(median 
range)
PULSE 
(per min) 
(median 
range)
YOUNG
median 29 
range 21-36 
years
Supine
*
117
* * *
72 60
98-113 69-92 53-65
Erect
**
119
* * * *
87 74
101-138 61-94 53-83
ELDERLY
median 70 
range 65-78 
years
Supine
*
146
***
102 62
127-187 78-127 60-70
Erect
**
157
* * * *
107 64
105-205 83-133 60-79
k ** *** 01p < 0.005 p < 0.05 p < 0.
TABLE 2: Volunteer erect and supine blood pressure
and pulse measurements.
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Plasma noradrenaline concentrations were significantly 
higher in the elderly group in both supine and standing 
positions (Table 3). As with blood pressure the median 
incremental rise on moving from the supine to standing 
position was the same in each group (76% in the elderly 
and 77% in the young).
At the highest noradrenaline infusion rate supine systolic 
pressure increased by a median of 8.5% in the old and 10% 
in the young,while diastolic pressure increased by 3.0% in 
the old and 8.0% in the young. There was no significant 
difference in blood pressure changes between the groups 
during noradrenaline infusion (Table 4). In neither old 
nor young was there any change in pulse rate during the 
noradrenaline infusions.
The analysis of the infused noradrenaline solutions at the 
end of each experiment confirmed the expected 
concentrations within +7.0%.
Pre-infusion, basal plasma noradrenaline levels were 
stable by 20 minutes and no further rise in noradrenaline 
concentration occured after 5 minutes standing. Steady 
state plasma levels of noradrenaline were achieved by the 
eighth minute of the noradrenaline infusions.
Noradrenaline clearance in the elderly subjects was not 
significantly different from values obtained for the 
young. The values for clearance at each of the four 
infusion rates were the same in the two age groups
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SUPINE
(median
range)
ERECT
(median
range)
YOUNG 
(n.mol/1)
*
2.6 
1.4 - 3.4
**
4.7 
1.8 - 6.0
* **
ELDERLY 4.0 6.8
(n.mol/1)
2.5 - 6.2 4.5 - 10.1
k **
p < 0.01 p < 0.01
TABLE 3: Plasma noradrenaline concentration in
young and elderly volunteers: erect and supine
position
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INFUSION RATE 0 
ug/kg/min
0.01 0.02 0.04 0.06
YOUNG
SYST BP (mmHg)
median 117 
range 98-133
114
95-125
113
100-135
130
108-135
127
111-145
DIAS BP (mmHg)
median 72 
range 69-92
80
70-95
80
78-100
86
72-90
79
68-85
PULSE (per min)
median 60 
range 53-65
58
50-61
59
50-62
50
44-62
59
52-80
ELDERLY
SYST BP (mmHg)
median 154 
range 126-187
140
130-193
135
128-205
160
140-205
165
130-214
DIAS BP (mmHg)
median 102 
range 78-127
105
80-127
100
80-130
100
85-128
100
73-121
PULSE (per min)
median 63 
range 50-77
68
50-70
60
55-70
60
60-75
67
57-75
TABLE 4: Effect of noradrenaline infusion rates on
pulse and blood pressure
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(Table 5). Since the elderly subjects were generally 
heavier than the young the clearance data were also 
calculated with regard to subject weight but again there 
was no significant difference between the two groups:
- 1  -i
old, 55 ml.kg .min (range 33-111),
-1 -1 -1 young, 67 ml.kg .kg . m m  ) .
The rate of spillover of noradrenaline was significantly 
greater in the elderly both in the supine and standing 
positions (Table 6). Median values were (supine position)
. - i  . - i
10.3 nmol.min in the young and 19.7 nmol.mm in the
old (p < 0.05) and (standing position) 17.2 nmol.min 1 in
. -1 .the young and 29.2 nmol.mm in the old (p < 0.01).
The possibility that the increased rate of noradrenaline 
release in the elderly was associated with their generally 
higher level of blood pressure (pre-infusion) was 
investigated by generalized linear interactive modelling 
(Table 7). When systolic and diastolic blood pressure 
were removed from the full model there was no significant 
effect on residual sums of squares in either supine or 
standing positions. However age was found significantly 
to influence the sum of squares in both positions.
2.4 DISCUSSION
This study confirmed that in the elderly there was a 
higher basal plasma noradrenaline concentration compared 
to the young. This higher concentration was related to an
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Infusion rate 0.01 
(microgm/kg/min)
0.02 0.04 0.06
Young
Noradrenaline
(1/min)
clearance
(median 3.9 4.5 3.3 4.8
range) 1.5-9.8 2.9-7.1 2.5-5.2 2.7-6.1
Elderly
Noradrenaline
(1/min)
clearance
(median 3.6 3.6 3.9 4.1
range) 2.3-5.7 2.7-7.7 2.6-5.7 2.6-8.2
TABLE 5: Noradrenaline clearance calculated at
four infusion rates.
No difference between clearance values calculated 
at the different infusion rates (Friedman two-way 
alalysis of variance)
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SUPINE
(median
range)
ERECT
(median
range)
YOUNG
Noradrenaline
release
(n.mol/min)
*
10.3
5.3-17.6
**
17.2
11.0-36.4
ELDERLY
Noradrenaline
release
(n.mol/min)
*
19.7 
10.1-53.8
**
29.2
21.1-121.0
*
p < 0.05
* *
p < 0.01
TABLE 6: Plasma noradrenaline spillover; erect and
supine positions
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Model 1. Rn = + a2 (SBP) + a3 (DBP) + a4 (age)
Model 2. Rn = b1 + fc>2 (SBP) + b3 (DBP)
Model 3. Rn = c.^  + c2 (age)
Sum of 
squares
F P
Supine 
Model 1 
Model 2 
Model 3
523
745
545
5.1
0.25
0. 05 
NS
Erect
Model 1 922
Model 2 1625 9.2 0. 01
Model 3 1194 1.8 NS
TABLE 7: Investigation of relationship between
rate of noradrenaline entry to the circulation, 
blood pressure and age.
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increase in the spillover from noradrenergic terminals 
with no change in the rate of clearance from the plasma.
Calculation of noradrenaline kinetics and selection of 
sampling site
Before giving consideration to the reasons for the 
increase in transmitter spillover it is important to 
examine the origin of plasma noradrenaline taken from the 
antecubital vein. Noradrenaline in the forearm venous 
plasma originates from two main sources: (i) release from
the total peripheral noradrenergic nervous system and,
(ii) local release from the sympathetic nerves in the 
forearm (see Figure 2). Noradrenaline is both cleared 
from and released into the circulation by the tissues of 
the forearm. Approximately half the noradrenaline in the 
plasma taken from the antecubital vein originates from the 
forearm tissues (47). The concentration of noradrenaline 
in plasma taken from the arterial tree or from right heart 
catheterisation (mixed venous blood) may be more 
representative of "total body" spillover, but the lungs 
are also responsible for extraction and release of 
noradrenaline. There is therefore probably no site for 
blood sampling that can be considered ideal for the 
assessment of total body noradrenaline kinetics. Local 
variations in sympathetic activity may occur without 
altering the plasma noradrenaline concentration measured 
in peripheral plasma, e.g. in some patients with renal 
artery stenosis there is an increased spillover from the 
ischaemic kidney without any change in the venous plasma 
noradrenaline concentration (48) .
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NANANANA
Liver
Adrenal
glands
NA
ad :
Mixed venous sampling
Lungs
Arterial sampling — >
Peripheral
tissues
Antecubital sampling
NA ADR
Figure 2: Diagramatic representation of the source of
noradrenaline in blood taken from the antecubital vein. 
Approximately half of this noradrenaline originates from 
the tissues of the forearm.
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There is a greater extraction of catecholamines by deep 
rather than superficial forearm tissue and therefore the 
antecubital vein is preferable to the brachial when 
investigating noradrenaline clearance with infused 
noradrenaline (48) . The antecubital vein has the 
additional advantage because sampling is relatively 
non-invasive and is easily repeatable. Furthermore the 
antecubital plasma noradrenaline concentration has been 
shown to be similar to that obtained from simultaneous 
sampling from the femoral artery and vein and the 
pulmonary artery (63).
The method of calculating noradrenaline spillover and 
clearance used in this study was described by Fitzgerald 
et al (60). Calculation of noradrenaline clearance is 
made following intravenous infusion of exogenous 
noradrenaline to a steady state concentration. The 
endogenous spillover of noradrenaline is then measured 
simply by the product of the basal plasma noradrenaline 
concentration and the calculated clearance. In making 
these calculations three critical assumptions are made:
(1) steady state concentration has been reached, (2) the 
infusion of noradrenaline does not affect clearance or (3) 
the infusion does not affect endogenous spillover of 
noradrenaline.
The validity of the steady state assumption is supported 
by the results of the study and by the observations of 
other workers (60). It has been demonstrated that steady 
state supine levels are achieved by 2 0 minutes. In the
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standing position, no further rise in plasma noradrenaline 
concentration occurs after 5 minutes (37). These 
observations were confirmed by the results of this study. 
The concentration of noradrenaline at the eighth and tenth 
minutes of the infusion are the same.
Noradrenaline has been shown to increase its own clearance 
by a beta-adrenergic mediated mechanism (64). In this 
study there was no change in clearance of noradrenaline at 
the four different infusion rates (Table 5).
The possibility that the infusion of noradrenaline 
affected the rate of entry of endogenous noradrenaline 
into the circulation has to be considered. A possible 
mechanism for this would be activation of pre-synaptic 
alpha-adrenoceptors on the nerve terminal which would lead 
to a reduction in the rate of noradrenaline release. This 
would give an underestimate of noradrenaline clearance 
which would tend to become more pronounced with the 
increase in infusion rate. Again it should be emphasised 
that in this study there was no change in clearance with 
increase in the the infusion rate. Also the calculation 
of noradrenaline clearance is more dependent on the 
relatively large infusion rate of exogenous noradrenaline 
measured in micrograms per minute, compared to the rate of 
endogenous spillover which is measured in nanograms per 
minute.
The origin of the increased plasma noradrenaline 
concentration in the elderly has also been assessed by
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other investigators (Table 8). Esler et al (65) reached 
the opposite conclusion to this study. They found no 
change in the rate of spillover and a decrease in the rate 
of clearance of noradrenaline. Their technique was 
different from that employed here, involving the infusion 
of tritiated-noradrenaline at tracer concentrations. This 
has the potential advantage of not having a 
pharmacological effect. In the study by Esler et al (65), 
measurement of noradrenaline release is dependent on 
achieving a steady state concentration of tritiated- 
noradrenaline which was measured by the amount of 
radioactivity present in an extract of the plasma.
However it took 60 minutes for the radioactivity to reach 
steady state compared to the 8 minutes to steady state 
noradrenaline concentration in this study. Noradrenaline 
is rapidly metabolised in plasma with a half life of 
approximately 3 minutes (66) . This suggests that Esler et 
al (65) might have been measuring a mixture of 
tritiated-noradrenaline and tritiated-metabolites of 
noradrenaline. Veith et al (67) , also using a similar 
tritiated-noradrenaline technique, found that there was an 
increase in spillover of noradrenaline with age which was 
accompanied by a less significant reduction in clearance. 
Hoeldtke and Cilmi (68) demonstrated an increase in 
spillover with no change in clearance with age. Once 
again questions arise about the presence of tritiated- 
metabolites of noradrenaline which would introduce errors 
into the calculations of noradrenaline spillover and 
clearance.
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NORADRENALINE KINETICS AND AGE
SPILLOVER CLEARANCE AUTHORS
No change Reduced Esler
et al 1981 (65)
Increased No change Hoeldtke 
et al 1985 (68)
Increased Reduced Veith 
et al 1986 (67)
Increased No change MacGilchrist 
et al 1988 (70)
Increased No change Poehlman 
et al 1990 (71)
TABLE 8: Studies of the origin of the increased
plasma noradrenaline concentration in the elderly: 
Tritiated-noradrenaline techniques.
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Howes et al (69) attempted to improve the assay for 
tritiated-noradrenaline in plasma by introducing a step to 
separate the metabolites with high performance liquid 
chromatography. In this study after 3 0 minutes of 
constant rate infusion with tritiated- noradrenaline only 
57% of the radioactivity measured was noradrenaline and 
this fell to 44% after 90 minutes. Using this assay, 
MacGilchrist et al (70) were able to confirm the present 
finding of a increase in the spillover of noradrenaline 
with age with no accompanying change in clearance. The 
present study suffers the potential disadvantage of using 
small but pharmacological doses of noradrenaline but has 
the considerable advantage of a highly specific 
noradrenaline assay which is unaffected by the presence of 
metabolites.
In a recent study (71) which examined the effect of 
physical activity and age on the release and clearance of 
noradrenaline, there was no change in the rate of 
clearance with age. Plasma noradrenaline levels and 
noradrenaline spillover were highest in elderly males who 
took regular exercise.
Factors affecting noradrenaline kinetics in the elderly 
The factors controlling noradrenaline spillover into 
plasma are complex and some possibilities are listed in 
Table 9.
An obvious reason for the increased spillover could be an 
increase in sympathetic activity with age. Support for
56
Age related factors that could affect noradrenaline
spillover.
1. Extent of tissue sympathetic innervation.
2. Amount of sympathetic nerve activity
3. Amount of noradrenaline released per nerve impulse
4. Activity of presynaptic adrenoceptors involved in the 
regulation of noradrenaline release
5. Degree of reuptake into nerve (and or other tissue)
6. Activity of mono-amine oxidase and catechol-O-methyl 
transferase
7. Size of synaptic cleft.
8. Permeability of tissue between synaptic cleft and 
lumen of vessel
Table 9: Some of the factors which might change with age
and cause an alteration in noradrenaline spillover into 
the circulation.
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this suggestion comes from a study where sympathetic 
activity in the peroneal nerve was monitored using dermal 
electrodes. Both plasma noradrenaline concentration and 
age correlated with sympathetic nerve activity (72) . The 
concentration of noradrenaline has been measured in human 
posterior tibial artery, obtained at post mortem, and in 
biopsy specimens of the cervix uteri. In both, the 
concentration of noradrenaline decreases with age (66). 
There is also histochemical evidence of a reduction of 
noradrenaline in human sympathetic ganglia (73). Taken 
together, these findings might suggest that there is 
increased sympathetic activity with age with an increase 
in release of noradrenaline accompanied by a reduction in 
the stores of noradrenaline in innervated tissue.
The sympathetic control of blood vessels is influenced by 
baroreceptors which when stimulated cause reduction in 
sympathetic activity and an increase in vagal tone. The 
effect of age on the responses of the baroreceptor reflex 
has been investigated (1). The effect of infusing the 
pressor agent phenylephrine was investigated in a group of 
volunteers aged 19-66 years. Increasing age was associated 
with a reduction in the sensitivity of the baroreceptor 
reflex. Another group of investigators (74) used a 
variable pressure neck chamber to study the responses of 
the carotid baroreceptors. They confirmed the reduction 
in efficiency of the receptors seen in the elderly but 
demonstrated that this only affected the control of heart 
rate, as the ability to alter blood pressure was 
preserved. Shimada et al (75) examined the effect of age
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on baroreceptor sensitivity in relation to plasma 
noradrenaline concentration. Using multiple regression 
analysis, when the influence of reduced baroreceptor 
sensitivity was eliminated, age was no longer associated 
with an increase in plasma noradrenaline. The authors 
therefore suggested that the reduction in sensitivity of 
the baroreceptor with increasing age resulted in an 
increase in sympathetic activity, and therefore an 
increase in plasma noradrenaline concentration. This view 
is almost certainly an oversimplification, as the studies 
with the variable neck chamber (74) demonstrated that the 
splanchnic circulation was principally involved in blood 
pressure regulation. However the splanchnic circulation 
does not contribute signficantly to the peripheral venous 
noradrenaline concentration (76), as noradrenaline 
released from the mesenteric nerves enters the portal 
venous system and is extensively metabolised on the first 
pass through the liver. On the other hand a considerable 
proportion of the noradrenaline measured in the peripheral 
venous plasma is derived from the skeletal muscle 
circulation, which appears not to be substantially 
affected by the baroreceptor reflex (74).
An attempt has been made to examine the effect of age on 
the rate of noradrenaline synthesis in the sympathetic 
nervous system (68). The technique involves an analysis 
of noradrenaline metabolite excretion in the urine. The 
authors demonstrated that there was no change in the rate 
of production of noradrenaline with age; however, there 
are limitations with this method - e.g. the difficulty in
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separating catecholamines released from the sympathetic 
nervous system from those released from the adrenal 
medulla and brain.
The rate of release of noradrenaline from the sympathetic 
nerve terminal is modified by several different 
presynaptic receptors. Stimulation of presynaptic 
alpha-2-adrenoceptors results in a reduction of 
noradrenaline release. The physiological importance of 
the presynaptic alpha-2-adrenoceptor is not yet 
established. In isolated human pulmonary arteries 
noradrenaline release was inhibited by
alpha-2-adrenoceptor agonists (77). However with studies 
i n  v i v o ,  the role of these receptors is less clear. The 
difference in plasma noradrenaline concentration between 
the brachial artery and antecubital vein is not altered by 
arterial infusion of the alpha-2-adrenoceptor agonist 
clonidine (78). However this study only measured the 
difference in arterio-venous concentration which does not 
necessarly reflect noradrenaline release from nerves, as 
the muscles of the arm both release and remove 
noradrenaline from the circulation. Clonidine did produce 
a dose related reduction in noradrenaline spillover when a 
tritiated-noradrenaline tracer technigue was employed 
(79) . It is of interest that even though the release of 
noradrenaline was reduced by clonidine, the overall plasma 
noradrenaline concentration remained unchanged.
There is little information on the effect of ageing on 
presynaptic alpha-2-adrenoceptor function. In an
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exa.inina.tion of isolated saphenous veins taken from 
patients of different ages, there was no change in 
presynaptic alpha-2 activity (80). This was confirmed by 
an i n  v i v o  study of the effect of clonidine on 
tritiated-noradrenaline kinetics in subjects of different 
ages (81).
There are no studies on the effect of age on other 
presynaptic receptors, e.g. beta-adrenoceptors or 
angiotensin receptors.
Spillover of noradrenaline into the plasma is not only 
influenced by the rate of release from the neurone but 
also by the rate of removal from the synaptic cleft. The 
principal mechanism for removal is reuptake into the 
neurone (uptake-1) which accounts for approximately 8 0% of 
the noradrenaline released (39). The noradrenaline is 
then either taken up into the intraneuronal vesicles or is 
metabolised by cytoplasmic mono- amine-oxidase (MAO). 
Extraneuronal uptake of noradrenaline (uptake-2) occurs i n  
v i t r o  (although there is evidence that uptake-2 does not 
occur i n  v i v o ) (41). There is extraneuronal metabolism of 
noradrenaline by catechol-O-methyl transferase (COMT).
There is some indirect evidence that uptake-1 may be 
deficient with increasing age (68) . This evidence is 
derived from a study of the excretion of different 
metabolites of noradrenaline. With increasing age there 
was a reduction in the MAO metabolites with a relative 
increase in the COMT metabolites. This suggests an
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increase in extra-neuronal metabolism, perhaps as a result 
of a decrease in the efficiency of uptake-1. However the 
same result could arise from a diminution in the 
efficiency of MAO with age similar to the decline in 
oxidation of certain drugs e.g. diazepam (82). There is 
no direct evidence for any change in the activity of MAO 
with age. There is evidence that the activity of COMT 
does not change with age (83).
In summary, this study demonstrated that in plasma taken 
from the antecubital vein the age related increase in 
plasma noradrenaline concentration was related to an 
increase in spillover rather than a decrease in clearance. 
There is evidence in the literature to suggest that this 
increased spillover of noradrenaline may be associated 
with an increase in sympathetic nerve traffic, or a 
decrease in the efficiency of neuronal reuptake, or a 
combination of both. However other mechanisms not yet 
studied, such as the influence of age on presynaptic 
alpha-2-adrenoceptors or angiotensin receptors, may be 
important.
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CHAPTER 3
THE EFFECT OF AGE ON THE RESPONSES OF HUMAN ISOLATED 
ARTERIES TO NORADRENALINE
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THE EFFECT OF AGE ON THE RESPONSES OF HUMAN ISOLATED 
ARTERIES TO NORADRENALINE
3.1 INTRODUCTION
Increasing age is associated with a decrease in the 
activity of the cardiac beta-l-adrenoceptor (84). It is 
not known whether this is related to the increased 
spillover in noradrenaline observed in Chapter 2.
This study was designed to examine the responses of the 
vasoconstrictor alpha-adrenoceptors with increasing age. 
Although it is relatively easy to stimulate alpha- 
adrenoceptors i n  v i v o ,  interpretation of the results of 
such a study is made difficult by the presence of 
cardiovascular reflex activity which also has been shown 
to change with age in man (1) . A further complication of 
such a study is the possibility that the disposition of 
the drugs used in the study would be altered by age. It 
was therefore decided to study human isolated arteries 
obtained from patients undergoing abdominal surgery. Such 
an i n  v i t r o  study avoids cardiovascular reflex activity.
3.2 METHOD 
Selection of arteries
Arteries were obtained from patients undergoing intra­
abdominal surgery at Stobhill General Hospital or the
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Southern General Hospital, Glasgow. All surgery was 
elective m  nature and was carried out by the departments 
of general surgery (gastrectomy or bowel resection) or 
gynaecology (hysterectomy).
In each case clinical details of each patient were 
gathered from the hospital case records. In particular 
diagnosis, blood pressure, drug history and past medical 
history were recorded. Details of the premedication and 
anaesthetic agents used were also noted.
Patients were excluded from the study if they were known 
to suffer from autonomic neuropathy, diabetes mellitus, 
hypertension, ischaemic colitis, treated or untreated 
thyroid disease or were receiving drugs prior to surgery 
known to modify sympathetic vascular activity. Arteries 
were excluded from the study if they were macroscopically 
diseased.
The arteries were collected at the time of surgery. Once 
the bowel resection or hysterectomy was carried out, the 
surgical specimen was immediatedly dissected and a length 
of artery removed. In colonic or small intestine surgery, 
a section of mesenteric artery was removed and in 
gastrectomy specimens, a section of gastric artery was 
obtained. Where hysterectomy was carried out, a section 
of the uterine artery was removed.
The artery specimen was then placed in ice cold 
physiological Krebs solution which had previously been
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gassed with 95% oxygen and 5% carbon dioxide, and 
thereafter immediately taken to the laboratory for further 
analysis.
Isolated artery laboratory technique
The arteries were then cannulated with 24 gauge stainless 
steel wire and the surrounding connective tissue dissected 
free with the help of a dissecting microscope. Care was 
taken to minimise damage to the adventitia which contains 
the sympathetic plexus. The artery was then cut into a 
helix, at an angle of 3 0° to the longitudinal axis (85) 
(Figure 3). This has the effect of producing a spiral 
strip of vascular smooth muscle which is then placed in an 
organ bath containing Krebs solution, (Figure 4). The 
Krebs solution had the following composition (mmol/1):
NaCl 118, NaHC03 24.97, KH2PC>4 1.25, KCl 4.75, CaCl2 2.54, 
MgSC>4 1.19 and glucose 1.11. The solution was gassed with 
95% oxygen and 5% carbon dioxide throughout the 
experiment. The bath was maintained at 37°C with a water 
jacket and a thermostatically controlled circulation pump 
(Churchill). Tension was measured under isometric 
conditions by a Grass FT03 force displacement transducer, 
and recorded by a Grass Polygraph ink pen recorder (Grass 
Instruments).
Initial resting tension was set at 1 gm and then the 
tissue was left for one hour to equilibriate.
The responses of the arterial strips to noradrenaline were 
then assessed. Noradrenaline (Sigma) was added to the
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Figure 3: Preparation of the arterial helix.
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Figure 4: The arterial strip is suspended in a 
physiological solution maintained at 37 degrees Celcius. 
Tension is recorded isometrically by a Grass FT03 
transducer.
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organ bath in a cumulative manner. The concentration of 
noradrenaline in the bath ranged from 10~8M to 10~3M. 
Following the production of a maximum response the tissue 
was washed in fresh Krebs solution. The dose response to 
noradrenaline was repeated on at least two occasions for 
each artery. The results were taken as the mean of the 
responses. Dose responses to KC1 were also examined in 
the initial studies to determine the lowest concentration 
at which a maximum response could be obtained (8xlO-2M). 
The maximum response to potassium was determined in each 
tissue by increasing the concentration of KC1 in the bath 
to 8x 10“2M.
Statistical analysis
The dose response curves to noradrenaline were drawn using 
the Hill transformation (86) :
R
log [Norad] is plotted against log _ (---------)
1U Rmax - R
[Norad] is the concentration of noradrenaline in the bath, 
R is the magnitude of the corresponding contraction and 
Rmax is the maximum contraction produced by noradrenaline 
in that artery. This transformation converts the sigmoid 
dose-response curve into a straight line. From this line 
the concentrations of noradrenaline which produce a 50% 
maximum response, the ED^q , and a 5% maximum response, the 
ED5 , were calculated. The ED5Q is a measure of the 
sensitivity of the tissue to the drug. The ED^ may be 
regarded as a threshold concentration which produces a 
minimal response. The responses to noradrenaline are
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expressed as a percentage of the maximum response to 
noradrenaline. This allows comparisons of the 
sensitivities of arteries of difference sizes.
Responses were also expressed as a percentage of the 
maximum response to potassium. This allows comparison of 
the alpha-adrenergic contraction with that produced by a 
non-adrenergic receptor mechanism.
Results were analysed using age as a continuous variable 
and also with age divided into three groups, 30-49 years, 
50-69 years and above 70 years. Statistical analysis was 
by non-parametric methods (Spearman Rank Correlation and 
the Mann Whitney test).
3.3 RESULTS 
Patient selection
Arteries were studied from 20 patients whose ages ranged 
from 35 to 83 years. The clinical details of these 
patients are shown in Table 10. The arteries were 
obtained were 7 uterine, 9 mesenteric and 4 gastric. In 
general pre-operative medication consisted of a narcotic 
analgesic with atropine and anaesthesia was maintained by 
nitrous oxide and oxygen with or without halothane. All 
patients received skeletal muscle relaxants.
Responses to noradrenaline
Figure 5 shows the responses to noradrenaline for three
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AGE SEX ARTERY DIAGNOSIS DRUG HISTORY
36 f uterine menorrhagia none
39 f uterine menorrhagia none
40 f uterine pelvic inflam none
42 f mesenteric Crohns disease salazopyrin
45 f uterine menorrhagia diazepam
46 f uterine menorrhagia phenobarbitone
49 f uterine menorrhagia none
52 f mesenteric carcinoma paracetamol
53 f uterine fibroids none
59 m mesenteric carcinoma none
62 m mesenteric carcinoma none
64 f mesenteric carcinoma none
71 f mesenteric carcinoma none
71 m mesenteric diverticular
disease
thiazide
lactulose
71 f mesenteric carcinoma none
72 f gastric carcinoma none
73 m gastric carcinoma none
77 m gastric peptic ulcer cimetidine
81 f gastric carcinoma none
83 f mesenteric carcinoma none
TABLE 10: Climical details (Isolated artery study)
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Figure 5: Responses of arterial strips to
noradrenaline in the three age groups: 
Young (30 - 49 years,’ n = 7)
Middle aged (50 - 69 years, n = 5)
Elderly (70 + years, n -S)
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age groups; young (median 42, range 36-49 years, n = 7), 
middle-aged (median 59, range 52-64 years, n = 5) and 
elderly (median 75, range 71-83 years, n = 8) . 
Noradrenaline response is expressed as a percentage of the 
maximum noradrenaline response. There was no signficant 
difference in the dose response curves of the three 
groups.
The values for EDC_ and EDC for the arteries of the50 5
different age groups are shown in Table 11. Once again 
there is no significant difference between the groups.
The responses to noradrenaline, expressed as a percentage 
of the maximum potassium chloride response were similar at 
all ages: median 103% (range 75-229%).
Analysis of the subgroups demonstrated that there was no 
difference between the ages of the males (median 71, range 
59-77 years) and females (mean 52, range 36-83 years). 
There was no differences in the ED^ or ED5Q between the 
sexes. However there was a significant difference between 
the ages of patients with benign conditions (mean 50, 
range 36-77 years) and those suffering from malignant 
diseases (mean 69, range 52-83 years) (p = 0.007) but 
there was no difference in the ED5 or ED5Q (Table 12).
The mean ages of the patients from whom uterine arteries 
were obtained (44 years) was significantly lower than that 
for the mesenteric arteries (64 years) (p = 0.006) and the 
gastric arteries (76 years) (p = 0.01) (Table 13). There 
was a significant difference in the threshold response to
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AGE
median
(range)
EDp-XlO M 
median 
(range)
EDR XlO M 
median 
(range)
YOUNG 42 21.8 2.9
(n=7) 36-49 5.3-48.2 1.1-7.8
MIDDLE
AGED 59 31.2 2.7
(n=5) 52-64 7.2-91 0.9-6.1
ELDERLY 72 40.8 2.8
(n=8) 71-83 4.5-282 1.9-22.4
TABLE 11: Noradrenaline response in young, middle
aged and elderly: Threshold (ED5) and sensitivity
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AGE
median
(range)
EDcxlO M 
median 
(range)
ED XlO M 
median 
(range)
BENIGN
*
50 27 3
(n=10) 36-77 4.5-57.3 1.1-7.8
MALIGNANT
*
69 71 5
(n=10) 52-83 7.2-282 0.9-22.4
*
P = 0.007
TABLE 12: Noradrenaline response in arteries from
patients suffering from malignant and benign pathology 
Threshold (ED5) and sensitivity (ED5Q).
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AGE
median
ED X10"8M 
median
ED X10 M 
median
(range) (range) (range)
UTERINE
*
44
**
22 3
(n=7) 36-53 5.2-42.6 1.1-6.4
MESENTERIC
*
64
**
51 4
(n=9) 43-83 7.2-94.6 0 vx> 1 00
GASTRIC
*
76 91 8
(n=4) 72-81 4.5-282 2.0-22.4
Uterine vs mesenteric age p = 0.006 
Uterine vs gastric age p = 0.01
** Uterine vs mesenteric threshold p = 0.03
TABLE 13: Noradrenaline response in uterine,
mesenteric and gastric arteries: Threshold (ED^)
and sensitivity (ED5Q).
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noradrenaline (ED^) between the uterine arteries (mean 2.3 
- 7
x 10 mol) and the mesenteric arteries (mean
5.1 x 10”7mol) ( p = 0.03). This difference, although
statistically significant, is small in comparison with the 
range of noradrenaline concentrations used in this study. 
The difference is also small in comparision with the range 
of threshold concentrations, uterine, 5.3 x 10~8 to
- 7  * O  _  ' ' j
4.3 x 10 M and mesenteric, 7.2 x 10 to 9.5 x 10 M.
Systolic blood pressure rose with the age of the patient 
(p = 0.003). There was no significant difference with 
diastolic pressure with age. However although the median 
diastolic pressure was the same in both sexes (90 mmHg) 
the males had marginally higher diastolic pressures (range 
90 - 130mmHg) than the females (range 60 - 95mmHg) (p = 
0.04). There was no relationship between the systolic or 
diastolic pressure and the threshold response (ED5Q) or 
the sensitivity of the arteries to noradrenaline (ED5Q) .
3.4 DISCUSSION
Responses of arteries from different sites 
In these arteries there was no change in response to 
noradrenaline over the age range 35 - 83 years. However, 
these arteries came from different regional circulations. 
The responses to noradrenaline of human isolated human 
arteries taken from different sites have been studied and 
found to be similar (87). Another study demonstrated that 
human pulmonary and crural vessels had a greater maximum
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response with noradrenaline when compared to potassium but 
in mesenteric arteries, the noradrenaline response was the 
greater (88) . In the uterine, colonic and gastric 
arteries studied in this series there was no significant 
difference in the sensitivity to noradrenaline (ED5Q). 
There was, however a small difference between the 
threshold response (ED5) in the uterine arteries compared 
with mesenteric vessels. The uterine arteries came from a 
younger population of patients than the mesenteric or 
gastric arteries and it is possible that the change in 
threshold response or other unrecognised differences 
between the reponses of the different arteries have 
obscured an age related change.
Influence of sex
A recent study has shown differences in responses to 
adrenergic drugs between the sexes (89). In men, but not 
women, brachial artery infusion of clonidine and 
phenylephrine produced a dose related vaso- constriction 
and isoprenaline a dose related vasodilatation. In the 
present study there were no differences in the responses 
between the sexes. Nevertheless the youngest patients 
were all female (Table 10) and this disparity also could 
obscure age related changes.
Influence of disease
Malignancy and diabetes are recognised causes of 
neurological disease including autonomic neuropathy.
There are no reports of the effect of autonomic neuropathy 
on the responses of human isolated arteries. In these
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arteries malignancy was only found in middle aged and 
oldest patients. Malignancy-induced autonomic changes may 
have gone unrecognised but there was no clinical evidence 
of such disorder in the case records of these patients.
Hypertension has been shown to reduce the sensitivity of 
post-mortem human digital arteries to noradrenaline (90). 
Other studies using temporal (91) and intra-abdominal (92) 
arteries taken from living patients have not confirmed 
this finding. The current study found no relationship 
between systolic or diastolic blood pressure and the 
sensitivity to noradrenaline. The diastolic blood 
pressure recordings were higher in the males, one patient 
had a pre-operative level of 13 0mmHg. He had not 
previously been recognised as hypertensive. The 
incidence of atherosclerosis increases with age. Moderate 
or severe atherosclerosis has been shown to inhibit the 
responses of human isolated coronary arteries to the 
vasodilatation produced by isoprenaline but not to the 
vasoconstrictor effect of nordrenaline (93). In this 
study no artery had macroscopic evidence of 
atherosclerosis.
Influence of tissue storage
Storage of innervated human arteries ( 3 - 1 4  days) has 
been shown to increase the sensitivity and maximum 
response to nordrenaline (94). This can probably be 
explained by denervation supersensitivity due to receptor 
up-regulation. Stored arteries also tended to produce 
spontaneous rhythmic contractions which may be due to
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unstable membrane potentials or even prostaglandin 
synthesis. In this study the arteries were examined 
within 2 hours of surgery.
Site of vascular aloha-adrenoceptors
Noradrenaline produces contraction of vascular smooth 
muscle by activation of alpha-adrenoceptors. It is now 
recognised that both alpha-1 and alpha-2-adrenoceptors are 
present on the smooth muscle of human mesenteric veins 
(95,96). They may also be present in human mesenteric 
arteries but appear to be functionally unimportant. It is 
thought that the alpha-l-adrenoceptor is situated at the 
neuroeffector junction and is predominantly affected by 
neuronally-released noradrenaline. On the other hand the 
alpha-2-adrenoceptors occur near the intima of blood 
vessels and are stimulated by circulating catecholamines 
(97) . There was no attempt in this study to identify or 
differentiate between the responses of the different 
alpha-adrenoceptors.
Tissue preparation
The techniques used to study human isolated arteries have 
been reviewed by Moulds (98) . The spiral strip 
preparation is easy to prepare and gives excellent and 
reproducable concentration-effect curves. They have the 
disadvantage of being less physiological than studies 
which involve the measurement of tension in ring segments 
of arteries. Both techniques are less physiological than 
intraluminal perfusion experiments. However with 
perfusion studies responses are not as easy to compare
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beteeen vessels of different size. There is also a longer 
delay between administration of drug and response than is 
seen in the spiral strip method.
Isometric tension was measured in this study even though 
it is less physiological than isotonic tension (98). 
Isotonic monitoring is more sensitive but there tends to 
be an "all or none" response which makes the construction 
of dose response curves difficult.
Another problem in the interpretation of studies of 
isolated arteries is the influence of endothelium-derived 
relaxing factor (EDRF). This is a powerful vasodilator 
substance (possibly nitrous oxide) that is released by the 
endothelial cells of almost all blood vessels in both 
reptiles and mammals (Reviewed: 99) . There is some 
experimental evidence to show that ageing impairs 
endothelium-dependent vasodilatation (100). The removal 
of endothelium from rat arteries during i n  v i t r o  studies 
enhanced the effect of alpha-2-adrenoceptor mediated 
contraction (101). The effect was less on 
alpha-l-adrenoceptor mediated contraction. There have 
been very few studies on the role of endothelium in human 
isolated arteries. The contractions of human isolated 
coronary arteries to noradrenaline (102) and isoprenaline 
(103) are endothelium-independent while contraction to 
substance P is endothelium-dependent (102). In the 
present study it is not known whether the endothelium was 
intact. The use of the 24 gauge stainless steel wire in 
the production of the spiral strip is more than likely to
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cause endothelial damage. This damage would have occurred 
with all the arteries and would not have been expected to 
affect any age group more than any other.
Results of other studies on acre and alpha—adrenoceptors 
Since publication of the results of this study (104) there 
have been two further studies involving age and the 
sensitivity of human isolated arteries to nordrenaline.
The first involved the responses of isolated digital 
arteries and metacarpal veins obtained at at post mortem 
(105). There was a significant positive correlation 
between patient age and maximum response to noradrenaline 
when expressed as a percentage of the maximum potassium 
response in males but not females. There was no change in 
the sensitivity of the arteries as measured by the ED5Q. 
The second study was on the effects of drugs on human 
isolated coronary arteries (93). These arteries were 
obtained from kidney donor patients whose hearts were not 
used for transplantation or from hearts intended for 
transplantation but not used because of complications in 
the recipient. A third group of coronary arteries were 
obtained from patients dying of cardiac disease. The 
responses to noradrenaline were unaffected by age or 
disease. Obviously arteries can undergo autolysis 
post-mortem or alternatively could demonstrate the 
denervation supersensitivity that occurs with storage 
(94) . However it has been shown that there is no 
significant change in the sensitivity of postmortem 
digital arteries for up to 60 hours after death, when the
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body is kept in refrigeration (87) .
There is therefore general agreement that in the human 
isolated arteries studied there is no change in the 
sensitivity to noradrenaline with increasing age. It is 
clearly possible that the relative contribution of alpha-1 
and alpha-2-adrenoceptors to the overall contraction could 
change with age. This would not be demonstrated with the 
use of noradrenaline which is a non- selective 
alpha-agonist. However, due to the insignificant 
contribution of alpha-2-adrenoceptors to the contraction 
of human mesenteric arteries (95,96) this seems unlikely. 
It is therefore reasonable to conclude that there was no 
change in the sensitivity of the alpha-l-adrenoceptor with 
increasing patient age.
Unlike the human mesenteric artery, contraction of the the 
saphenous vein is mediated principally by alpha-2- 
adrenoceptors. In an elegant study, the effects of the 
alpha-1- adrenoceptor antagonist prazosin and 
alpha-2-adrenoceptor antagonist yohimbine were compared in 
veins precontracted with noradrenaline (80) . Yohimbine 
was less potent with increasing age while there was no 
change with prazosin. This provides evidence that while 
the alpha-l-adrenoceptor remains unchanged with increasing 
age, the postsynaptic alpha-2- adrenoceptor becomes less 
sensitive. These results are even more interesting 
because it was shown that the sensitivity of the 
presynaptic alpha-2-adrenoceptor remained unchanged with 
age (80). There was no age-related difference in the
83
potency of alpha-2-adrenergic blockade at inhibiting the 
overflow of tritium evoked by electrical stimulation from 
veins pre-incubated with [3H]-noradrenaline. This lack of 
change in the presynaptic alpha-2-adrenoceptor has been 
confirmed by an i n  v i v o  study of noradrenaline kinetics 
where the the effect of the alpha-2-adrenoceptor agonist 
clonidine was unchanged with age (81) .
There have been few investigations in to the activity of 
the alpha-l-adrenoceptor with age i n  v i v o .  There is 
indirect evidence of a reduction in alpha-l-adrenoceptor 
activity from a study of groups of young and elderly 
volunteers (106). Comparisons were made of systemic blood
pressure responses to intravenous infusions of
phenylephrene before and after 1 mg oral prazosin. 
Responsiveness was expressed as the dose of phenylephrine 
required to raise mean arterial pressure by 2 0 mm Hg
(PD20). This dose was significantly higher in the elderly
group before prazosin. Prazosin produced comparable falls 
in blood pressure in both groups. Following prazosin 
administration the PD2Q was the same for both groups. The 
authors cautiously suggest that these results are not 
inconsistent with an age-related reduction in 
alpha-l-adrenoceptor responsiveness. A virtually 
identical study was carried out by Klein et al (107).
They came to the conclusion that although prazosin 
appeared to have a greater effect in the elderly, there 
was no change in the sensitivity of the alpha-l- 
adrenoceptor .
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Other investigators have tried to eliminate the influence 
of baroreceptor reflexes which may have complicated these 
i n  v i v o  studies (106,107). Vasoconstrictor tone was 
quantified by measuring the vasodilatation induced in the 
forearm during an intra-brachial arterial infusion of 
phentolamine (108). There was no difference in the 
increase in blood flow observed with age of the volunteer. 
The use of the non-selective alpha-antagonist phentolamine 
may have complicated the results by inhibiting, not only 
post-synaptic alpha-1 and alpha-2- adrenoceptors, but also 
presynaptic alpha receptors as well, causing an increased 
release of noradrenaline. Two studies have examined age 
related responses of the dorsal hand vein to noradrenaline 
(109) and phenylephrine (110). This technique involves 
measurement of movement in the wall of a dorsal hand vein 
with a freely moveable electrical coil which rests over 
the centre of the vein. The rate of infusion of drugs 
required was too small to cause measurable systemic effect 
(e.g. noradrenaline 50 ng/min). This method also allows 
for measurement of the dose required to produce a maximum 
response which is very unusual in i n  v i v o  research. As a 
result a reasonably accurate measure of drug sensitivity 
is possible - in this case the dose required to produce a 
50% maximum constriction (ED5Q) was similar to i n  v i t r o  
studies. There was no difference in the ED5Q in young or 
old volunteers, although the overall dose range was large 
(1.5 - 360 ng/min). Similarly there was no change in the 
dose of phenylephrine required to produce 50% or maximum 
venoconstriction.
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The dilator pupillae muscle is the only other alpha- 
adrenergic innervated tissue, known to me, to be studied 
for the effect of age. The alpha receptors are presumed 
to be of the alpha-1 type. The diameter of the 
dark-adapted pupil is reduced in the elderly perhaps due 
to decreased sympathetic dilator tone (111) . The 
dilatation produced by a single dose of phenylephrine is 
greater in the elderly, although the maximum dilatation 
reached is similar in young and old. This has been 
interpreted by the authors as evidence for diminished 
sympathetic nerve activity combined with an increase in 
postsynaptic alpha-1- adrenoceptor sensitivity.
Noradrenaline causes aggregation in human platelets due to 
activation of alpha-2-adrenoceptors. Some workers have 
reported that platelet aggregation occurs more readily in 
the elderly however others find no such relationship 
(Review: 112). In the platelet, cyclic adenosine 
mono-phosphate (cyclic AMP) production is stimulated by 
prostaglandin E1 (PGE^ and inhibited by 
alpha-2-adrenoceptor stimulation. Baseline cyclic AMP 
levels and production in response to PGE^ are unrelated to 
age but the ability of noradrenaline to inhibit cyclic AMP 
production was reduced in a fit group of healthy elderly
(112) . This reduction in inhibition with noradrenaline in 
the elderly was small and was not seen with the more 
potent agonist adrenaline. It is unlikely to be of 
clinical importance.
Platelets offer a readily accessible tissue and several
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groups have tried to study the effects of increasing age 
on adrenoceptor number. This is accomplished by measuring 
the binding of radio-labelled agonists or antagonists to 
intact platelets or to a preparation of platelet membranes
(113). Rather surprisingly, for what should be a 
relatively standard experiment, the results of these 
studies have been conflicting (Review: 114). There are 
reports of a reduction (115) or an increase (116) in the 
maximum number of binding sites with increasing age, while 
other studies have not demonstrated any change 
(112,117,118,119). The use of different ligands in these
studies may help to explain the variation in results.
3However, using [ H]-yohimbine as the ligand, an increase 
(116), a reduction (115) and no change (112,118) in 
platelet receptor number with age have all been 
demonstrated. Overall, there is no strong evidence to 
suggest a consistent change in receptor number with age.
Considerable caution should be exercised in the 
interpretation and extrapolation of results from platelet 
alpha receptor to alpha-l-adrenoceptors at other sites 
(120). The platelet alpha-2-adrenoceptor may be similar 
to other non-innervated peripheral receptors, for example 
the post junctional alpha-2-adrenoceptor. Both appear to 
respond to circulating catecholamines and will be 
regulated by the level of peripheral sympathoadrenal 
activity. In contrast peripheral presynaptic receptors 
will be under intrasynaptic regulation.
To date our knowledge of the influence of ageing on the
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sensitivity of human alpha-adrenoceptors is summarized in 
Table 14. There appears to be no change in the 
sensitivity of the adrenoceptors principally associated 
with the neuroeffector junction: the postsynaptic 
alpha—1—adrenoceptor and presynaptic alpha—2—adrenoceptor. 
There is evidence for a reduction in the sensitivity of 
the post synaptic alpha-2-adrenoceptor and for a slight 
reduction of the effect of the platelet alpha-2- 
adrenoceptor. There appears to be no change in the number 
of alpha-2-adrenoceptors on platelets. Both the 
post-synaptic alpha-2-adrenoceptor and platelet 
adrenoceptor are under the control of circulating 
catecholamines. Why then does age have such a 
differential effect on the ageing of human adrenoceptors ?
Continued exposure to a drug or hormonal agonist often 
leads to a blunted response to that agonist (113) . It 
would be attractive to relate the increased circulating 
levels of noradrenaline seen in the elderly to 
down-regulation of the postsynaptic alpha-2-adrenoceptor 
and to the lesser inhibition of cyclic AMP production seen 
in elderly platelets exposed to noradrenaline. Attempts 
have been made to demonstrate down-regulation of platelet 
adrenoceptors i n  v i t r o .  Incubation of platelets with high 
concentrations of adrenaline resulted in decreased radio­
ligand binding of [3H]-dihydroergotryptine, suggesting 
loss of active receptor sites (121). However this could 
not be repeated using the ligand [ H]-yohimbine (122).
This may be due to the non-specific nature of 
dihydroergotryptine which is known to bind to other
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IN VIVO (PRESYNAPTIC}
Alpha-2 Saphenous vein No change (80)
IN VIVO (POSTSYNAPTIC}
Alpha-1 Arteries 
and veins
No change (93,104,105)
Alpha-2 Saphenous vein Reduction (80)
PLATELET LIGAND BINDING STUDIES
Alpha-2 Increase 
No change
Reduction
(116)
(112,117,118,
119)
(115)
IN VIVO (PRESYNAPTIC}
Alpha-2 No change (81)
IN VIVO (POSTSYNAPTIC}
Alpha-1 Decrease 
No change
(106, 111)
(107,108,109,
110)
Beta-2 No change (36)
TABLE 14: Summary of studies of ageing and human
adrenoceptors.
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receptors, e.g. dopamine receptors. Platelets also 
accumulate adrenaline during i n  v i t r o  incubation. This 
retained adrenaline can later block the binding of 
radio-ligands leading to an incorrect conclusion that down 
regulation has occurred (113). There is now evidence from 
animal studies that the ageing may be associated with a 
loss of the ability to down-regulate autonomic receptors. 
Beta-adrenoceptors on young rat lymphocytes down-regulate 
with the acute stress of immobilisation (123). Receptors 
accessable to surface ligand binding were reduced by 45% 
(total receptor numbers remained unaltered). This was 
interpreted as an internal redistribution of receptors in 
response to stress. With middle aged and older rats (12 
and 2 6 months) there was no redistribution of 
beta-receptors with age.
The regulatory influences on the alpha-adrenoceptors at 
the neuroeffector junction are difficult to define. 
Nothing is known about the influence of age on the 
synaptic concentrations of nordrenaline. The evidence of 
increased spillover of noradrenaline in the forearm 
circulation has been presented (Chapter 2) . This does not 
necessarily mean that there is an increased concentration 
of neuro-transmitter at the synapse as clearly it can 
escape from the synapse into the surrounding cells, 
extracellular space and eventually into the circulation.
In summary, the evidence from human experiments virtually 
all agree with the findings of this study, that there is 
no change in the sensitivity of the vascular post-synaptic
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alpha-l-receptor with age.
I have not included in this discussion references to many 
animal studies. These frequently compare immature with 
mature animals rather than mature with senescent. 
Futhermore the relevance of studies on aged rats and other 
animals to human physiology remains unclear.
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THE INFLUENCE OF AGE ON THE DISPOSITION AND EFFECT OF
PRAZOSIN
4.1 INTRODUCTION
Increasing age is associated with a rise in the plasma 
concentration of noradrenaline (Chapter 2) but there is no 
change in the sensitivity of the vasoconstrictor 
alpha-l-adrenoceptor (Chapter 3). These observations not 
only relate to the physiology of ageing but also may be 
important to the actions of adrenergic drugs. Prazosin is 
a selective alpha-l-adrenergic antagonist, having high 
affinity but no intrinsic activity. The higher plasma 
concentration of noradrenaline in the old could in theory 
lead to a relative resistance to the hypotensive action of 
prazosin.
In man, prazosin also undergoes first pass metabolism with 
only 40-60% of an orally administered dose reaching the 
systemic circulation unchanged (124). This study was 
designed to examine the effect of increasing age on the 
disposition of prazosin and the associated changes in 
blood pressure and pulse in groups of young and elderly 
volunteers who were living independently in the community.
4.2 METHODS 
Volunteer selection
Fourteen volunteers took part in this study. Seven
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subjects were young and their ages ranged from 22 to 32 
and the other seven were elderly with an age range of 66 
to 78 years. All were living at home independently. The 
young were recruited from hospital staff and the elderly 
were recruited by the help of their General Practitioners. 
All subjects underwent a physical examination prior to the 
study and none had significant pathology. No volunteer 
had a past history of serious illness or was receiving any 
medication. All had normal haematological, biochemical 
indices and had normal electrocardiograms.
Experimental technique
Each subject was studied on two occasions at least 1 week 
apart. On one study day subjects received 1 mg of 
prazosin orally 3 hours after a light breakfast and 5ml 
blood samples were drawn through an indwelling venous 
cannula at 0, 15, 30, 60, 90, 120, 150, 180, 240, 300,
360, 42 0 and 480 minutes with the subject supine. On the 
other study day the young subjects received 1 mg and the 
elderly subjects 0.5 mg of prazosin gluconate (Pfizer) by 
rapid intravenous injection and samples were drawn from 
the other arm at the times given above and in addition at 
1, 2, 5, 10, 2 0 and 40 minutes.
Erect and supine blood pressure was recorded frequently 
during the injection of prazosin and at regular intervals 
during both study days using an automated sphygmomanometer 
(Bosomat).
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Plasma prazosin analysis
Whole blood was stored at -2 0°C until analysed by high 
pressure liquid chromatography using fluorescence 
detection (125) . This method has a coefficient of 
variation of 5 - 10 % over the concentration range 2
nmol/1 to 100 nmol/1. All samples were analysed within 4
weeks of being collected. Prazosin is stable in whole 
blood stored at -20°C for at least 6 months (125) .
Pharmacokinetic analysis
Blood concentration v  time data following intravenous
administration were fitted to a biexponential function of
the form:
Cp(t) = + Be-beta(t)
using a nonlinear least squares regression programme based 
on the Marquardt algorithm (12 6) with reciprocal weighting 
on a Varian V70 series computer. The slope of the 
disappearance phase after oral prazosin was estimated by 
fitting the terminal log-linear phase of the prazosin 
concentration-time curve to a monoexponential decay 
function using the nonlinear least squares computer 
programme. The area under the concentration versus time 
curve during the blood sampling period was calculated 
using the trapezoids rule. The extrapolated area beyond 
the last data point was calculated by dividing the 
concentration at the time of the last sample by the 
terminal slope obtained from the computer fit of the data 
following the intravenous injection. The total area under 
the curve (AUC) for oral or intravenous dosing was the sum 
of these two areas.
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The absolute bioavailability (F) , defined as the fraction 
of the oral dose which reaches the systemic circulation in 
unchanged form, and clearance (Cl) were determined by the 
following expression:
AUCoral/doseoral
F  ----------------------
AUC. „ /dose.
l . V . '  l . V .
Dose.
l.V.
Cl =
AUC.
l . V .
The first pass metabolism of prazosin is not saturable 
over a wide dose range: the AUC/mg following 5 mg to young 
subjects (127) is not greater than the AUC seen in the 
present study. The coefficients of the biexponential 
equation were used to calculate the volume of distribution 
at steady state according to standard techniques assuming 
a two compartment open model with elimination from the 
central compartment.
Statistical analysis
Comparisons between young and old were performed using 
non-parametric analysis: the Wilcoxon rank sum test and 
the Mann Whitney test.
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4.3 RESULTS
The young subjects ranged in weight from 61 to 87.2 kg 
(mean 77.5) and the elderly from 59.5 to 98 kg (mean 
77.8) .
Blood pressure changes following oral prazosin are shown 
in Figures 6-9 (changes expressed as percentage falls from 
baseline). In general, there were no differences between 
the falls in pressure observed between the young and 
elderly. Supine blood pressure fell less than that 
measured in the erect position.
Table 15 shows the coefficients of the biexponential 
equation to which the intravenous data was fitted. The 
elimination half-life of prazosin was the same following 
intravenous and oral administration both for the young 
group who received the same dose by each route (123 min 
i.v . ; 126 min oral) and for the elderly subjects who 
received a lower intravenous compared to oral dose (194 
min i.v.; 188 min oral).
The half-life, clearance, volume of distribution and 
bioavailability of prazosin in young and elderly subjects 
are shown in Table 16. Half life was significantly longer 
in the elderly subjects but clearance did not differ 
between the two groups whether when expressed in terms of 
unit weight (Table 16) or in absolute terms (308 ± 80 
ml.min ^ in the young, 274 + 84 ml.min in the elderly;
P > 0.1). Volume of distribution at steady state was
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MINUTES 
□  ELDERLY (g) YOUNG
Figure 6: Percentage fall in systolic
blood pressure (erect position) after 
lmg oral prazosin.
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Figure 7: Percentage fall in diastolic
blood pressure (erect position) after 
lmg oral prazosin.
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Figure 8: Percentage fall in systolic
blood pressure (supine .position) after 
lmg oral prazosin.
100
FA
LL
10
5-I
>
-5-
- 10 -
-15-
- 20-
-25-
-30-
-35-
-40 60 ' 90 ' 120 ' 150 ' 180 ' 240 ' 300 ' 360 ' 420 ' 400
' MINUTES 
□  ELDERLY 0  YOUNG
Figure 9: Percentage fall in diastolic
blood pressure (supine position) after 
lmg oral prazosin.
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A alpha B beta
Young 202 0.232 45.8 0.00573
±187 +0.187 ±13.7 ±0.0009
Old 84.5 0.172 18.0 0.00368
±42.4 ±0.13 ±3.1 ±0.0006
TABLE 15: Coefficients of the equation
Cp(t) = Ae”alpha t  + Be-beta t ' Young subjects 
received 1 mg and elderly subjects 0.5 mg of 
prazosin intravenously. Data are expressed as 
means ± s.d. The mean coefficients of determination 
for the fitted curves were 0.97 (young) and 0.933 
(old) . A and B have the units of nmol ; alpha and 
beta have the units of min 1
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T1/2 Cl VDss F
. -1 -1 -1 ( m m  (ml. m m  .kg (1
± sd) ± sd) ± sd) (± sd)
** * *
Young 123 3.94 0.63 0.68
+ 19.4 ± 0.73 ± 0.14 ±0.17
** * *
Elderly 194 3.53 0.89 0.48
+ 36.0 ± 1.0 ± 0.26 ± 0.16
* * k
P < 0.01 P < 0.05
T1/2
= elimination half life
Cl = clearance
V ,ss d
= volume of distribution at steady state
F = bioavailability
TABLE 16: Pharmacokinetic indices of prazosin in young
and elderly subjects (mean ± sd)
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significantly greater in the elderly both when in 
expressed in absolute terms (49.4 + 14.8 1 in the young 
and 69.2 ± 2 0.0 1 in the elderly; p < 0.05) and when 
analysed in terms of unit weight (Table 16) .
Bioavailability was significantly lower in the elderly 
than the young, less than half the orally administered 
drug reaching the systemic circulation in unchanged form 
(Table 16) . The total area under the curve per mg
. - i
(umol.mm ) were as follows: Intravenous: 9.0 + 2.5 
young; 10.2 + 2.9 old; oral: 6.1 + 1.7 young; 4.6 + 0.4 
old.
4.4 DISCUSSION
The elimination half life of many drugs that undergo
hepatic degradation has been shown to be prolonged in old
age (4,82). However a knowledge of half-life alone
provides only limited information about the changes in
disposition that might occur in the elderly. This is
because half-life (T ) is itself determined by both
1/2
clearance (Cl) and volume of distribution (V^) :
vd
T = -------- — X 0.693
1/2
Cl
Volume of distribution and clearance can be determined 
properly only from data produced by intravenous
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administration. Few pharmacokinetic studies in the 
elderly have been performed using intravenous drug 
administration, e.g: antipyrine (128), diazepam (22,24),
propranolol (19), chlormethiazole and lignocaine (129), 
nifedipine (130), aminophylline (131), nitrazepam (132) 
labetolol (13 3) , levodopa (134). Increasing age had no 
consistent effect on the disposition of these drugs. 
Antipyrine, nifedipine, levodopa and chlormethiazole 
showed a decreased clearance in the elderly. There is no 
change in the clearance of labetolol or nitrazepam. 
Aminophylline clearance is unchanged with age in healthy 
non-smoking volunteers. Nitrazepam, diazepam and 
lignocaine showed a significant prolongation of 
elimination half-life in the elderly but this was due to 
an increase in the volume of distribution rather than a 
fall in the clearance. There is no change in the 
elimination half life of levodopa with age - but this is 
because there is a parallel fall in both the rate of 
clearance and the volume of distribution with age.
This study demonstrates that prazosin also has a prolonged 
elimination half-life in the elderly which is due to an 
increase in the volume of distribution. The volume of 
distribution is largely determined by the physico-chemical 
characteristics of the drug. Lipophilic drugs will be 
able to distribute widely across membranes and also 
accumulate in adipose tissue. Ageing is associated with a 
reduction in lean body mass and increase in fat (23) . It 
might therefore be expected that lipophilic drugs would 
have an increased volume of distribution in the elderly.
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Prazosin is only modestly lipophilic (135) and the 40% 
increase in the volume of distribution in the elderly is 
small in comparison with the 200-300% increase in the 
volume of distribution of the much more lipophilic drug 
diazepam (24).
Prazosin, diazepam and lignocaine have in common not only 
the increase in the volume of distribution with no change 
in clearance in the elderly, but also their route of 
elimination: demethylation. However it is not possible to 
assume that demethylation is unaffected by age as 
chlordiazepoxide which is also metabolised by this 
pathway, has reduced clearance in the elderly (13 6).
The clearance of propranolol in the elderly has been 
studied by two groups of investigators. Castleden and 
George (19) demonstrated a reduction in clearance with age 
while Shneider et al (2 0) demonstrated that there was no 
change. The most likely explanation for this discrepancy 
is that the first study compared young fit volunteers with 
institutionalised, chronically disabled elderly. The 
second study examined young and elderly volunteers who 
were living at home. It is therefore than likely that the 
original conclusion that clearance is reduced by age alone 
is wrong - and that clearance is reduced by age in 
combination with disease. In the present study, all 
volunteers were living at home independently and none was 
receiving any medication.
The bioavailability of a drug is related to the degree of
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gastrointestinal absorption as well as to the degree of 
first pass metabolism. This study showed that in the 
elderly, there was 40% less unchanged drug reaching the 
systemic circulation compared with the young, it is 
probable that the enzymic pathways responsible for first 
pass metabolism are the same as that for systemic 
clearance. As there was no change in the systemic 
clearance of prazosin it is unlikely that the first pass 
metabolism is significantly altered with age. It is 
therefore possible to conclude that there is a reduction 
in the gastrointestinal absorption of prazosin with 
increasing age. The physiological changes that occur with 
age may help to explain this observation since there is a 
decrease in the liver mass (137) , a fall in intestinal 
blood flow (13 8) and the number of gastro-intestinal 
absorbing cells probably also decrease (139). There does 
not appear to be any change in the hepatic concentration 
of drug metabolising enzymes (140).
In this study there were only minor differences in the 
fall in blood pressure between the young and elderly 
groups. Basal blood pressure was higher in the elderly 
than the young and falls were expressed as a percentage of 
basal. The falls in blood pressure with intravenous 
administration of prazosin were similar, but the dose 
given to the elderly was half that given to the young. 
There were no consistent differences in the responses to 
lmg oral prazosin given to young and old. This is m  
contrast to a more recent study where elderly volunteers 
had a significantly greater fall in supine blood pressure
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when given 1 mg prazosin, erect blood pressure was not 
assessed (107) .
Since the publication of the results of this study (141) 
there has been one other study into the effect of age on 
the disposition of prazosin (142). This study involved 
two groups of normal volunteers: 10 young (19-30 years) 
and 5 older (54-62 years) . No change was seen in the area 
under the concentration-time curves or in the elimination 
half-life, between these two groups. The use of oral only 
dosing ignores any changes in bioavailability that may 
have occurred. The lack of change in the elimination 
half-life may reflect the relative youth of their 'older' 
volunteers when compared to the elderly in the present 
study.
The pharmacokinetic changes for prazosin described here 
are unlikely to be of major clinical importance. A 
prolonged elimination half-life caused by an increased 
volume of distribution will result in a longer time to 
reach steady state plasma concentration with regular 
dosing - but the final concentration will not differ from 
that seen in the young. However even the time to steady 
state is of little clinical importance for a drug with 
such a short half life as prazosin. The reduction in 
absorption is also unlikely be of significance for a drug 
where dose is titrated against effect.
A more important conclusion of this study is the 
importance of using of intravenous drug administration in 
studies which attempt to measure drug clearance.
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THE INFLUENCE OF AGE ON THE DISPOSITION AND EFFECT OF 
TRIMAZOSIN, ACEBUTOLOL AND TRIMAZOSIN
5.1 INTRODUCTION
The study described in this chapter adopts an experimental 
method which combines the measurement of drug effect and 
relates this to plasma drug concentration (54) . Using 
this approach it is possible to describe age related 
changes not only in the pharmacokinetics (drug 
distribution and metabolism) but also in the pharmaco­
dynamics (effect) of drugs.
Three antihypertensive drugs were studied: trimazosin, an 
alpha-l-adrenergic antagonist; acebutolol, a beta-1- 
adrenoceptor antagonist; and tolmesoxide, a peripheral 
vasodilator which acts directly on vascular smooth muscle.
Trimazosin is a quinazoline derivative, related to 
prazosin. It has a longer elimination half-life in the 
young than prazosin (143) and is extensively metabolised 
to 1-hydroxytrimazosin. This metabolite also has 
antihypertensive properties (144).
Acebutolol first undergoes hydrolysis and then 
N-acetylation to form diacetolol which is inactive (145).
Tolmesoxide undergoes hepatic metabolism to its sulphone 
metabolite which is then O-demethylated and excreted in
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the urine as a glucuronide conjugate (146).
This single blind, placebo controlled study was designed 
to examine the effect of age on the pharmacokinetics and 
pharmacodynamics of trimazosin, acebutolol and 
tolmesoxide. Drug effect was measured by the fall 
produced in systolic blood pressure.
5.2 METHODS 
Volunteer selection
The study was undertaken in 30 subjects aged 21 to 77 
years (15 male and 15 female) none of whom had any serious 
illness and who all had normal haematological and 
biochemical parameters. No volunteer smoked or was 
receiving drug therapy (including oral contraceptives) .
The subjects were recruited so as to obtain as far as 
possible a continuous spectrum of age; they were however 
subsequently arbitrarily divided into equal three groups 
of ten (5 male, 5 female) the three groups being 
classified as young, middle aged and elderly (Table 17) .
Experimental technique
The subjects attended fasting at 8 a.m. on 4 separate 
occasions with intervals of at least a week. An 
indwelling catheter was inserted into the antecubital vein 
and the subjects were then rested for at least half an 
hour at which time baseline measurements of erect and 
supine blood pressure and heart rate were made.
The drugs were administered in random order by intravenous
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Age Weight Male:Female
years kg
Young
mean
s.d.
range
24
2
21-28
61.0
10.8
48-77
5 : 5
Middle
aged
mean
s.d.
range
43
5
39-52
68.9
12.8
52-85
5 : 5
Elderly
mean
s.d.
range
69
5
62-77
64.7
9.5
55-79
5 : 5
TABLE 17: Volunteer Demographic Data for study
of pharmacokinetics and dynamics of trimazosin 
acebutolol and tolmesoxide
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injection into the other arm of either: placebo; 
trimazosin 100 mg; acebutolol 20 mg; and tolmesoxide 
100 mg.
Blood samples for drug analysis and blood pressure 
measurements were made at regular intervals over the 
following 10 hours.
Pharmacokinetic and pharmacodynamic analysis 
The drug and metabolite concentration data were fitted to 
a series of one and two compartment models and the 
parameters estimated by extended least squares fitting 
(147) . The goodness of fit of each model was judged using 
both the coefficient of determination and the z value for 
runs in the residuals. The models considered include 
those which incorporate an effect associated with both 
parent drug and metabolite (144) . Model comparison was 
based on the Akaike Information Criterion values (148) . 
From these fits the following parameters were derived; 
drug clearance, volume of distribution, drug elimination 
half-life and the ratio of the area under the metabolite 
and drug concentration time curves which represents a 
measure of the relative clearance of the metabolite.
Conventional analysis of blood pressure and heart rate was 
made on the basis of repeated measures analysis of 
variance and all results are expressed as mean + 1 
standard deviation. Pharmacokinetic and pharmacodynamic 
data was examined by two way analysis of variance and 
linear regression.
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Trimazosin
Trimazosin and its major metabolite 1-hydroxytrimazosin 
were measured simultaneously by high pressure liquid 
chromatography (HPLC) (149). The limit of detection of 
the assay for the parent drug and metabolite is l.Ong.ml”1 
and the inter-assay coefficients of variation across the 
assay range was 5.2% and 4.6% respectively.
The drug and metabolite concentrations were more 
appropriately fitted to an integrated 3-compartment model 
with two compartments describing drug disposition and one 
compartment for the metabolite concentrations. The most 
appropriate effect model was one in which effect was 
attributed to both parent drug and metabolite. This 
confirmed previous findings with intravenously 
administered trimazosin (144).
Acebutolol
The plasma concentrations of acebutolol and its major
metabolite diacetolol were determined by a sensitive,
specific HPLC assay (150). The limit of detection for
-1
both drug and metabolite was 20 ng.ml while the 
respective inter-assay coefficients of variation across 
the assay range were 4.2% and 5.6%.
The most appropriate kinetic model combined two 
compartments for drug disposition and one for metabolite 
arising from the central drug compartment.
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Tolmesoxide
Tolmesoxide and its major sulphone metabolite were 
measured by an HPLC assay (151). The assay limit for 
parent drug and metabolite was 5 ng.ml-1 and the 
inter-assay coefficients of variation across the assay 
range were 6.8% and 7.5% respectively. The most 
appropriate model was a two compartment (drug) and one 
compartment (metabolite).
5.3 RESULTS
Trimazosin
The pharmacokinetic parameters derived from simultaneously
fitting the plasma drug and metabolite concentration data
are given in Table 18. Although the drug clearance in the
. -1 -1elderly (0.6 + 0.1 m l . m m  .kg ) appeared to be less than
. -1 -1that m  the young (0.9 + 0.2 m l . m m  .kg ) the difference 
did not reach statistical significance. There was a 
related apparent difference in the ratio of the areas 
under the drug and metabolite concentration curves. The 
ratio for the young was 1.1 ± 0.2 in the young and 0.8 + 
0.1 in the old, again this did not reach statistical 
significance. However when age was treated as a 
continuous spectrum with the application of linear 
regression analysis there was a significant negative 
correlation with age (P < 0.005, r = -0.59) as shown in 
Figure 10. There was also a corresponding negative 
correlation between the ratios of the areas under the drug 
and metabolite concentration curves and age (p <0.005, 
r = -0.54), shown in Figure 11.
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Clearance A u y  BetaT1/2 Vdss
D . -1(min) (l.kg )
Young
mean
s.d.
range
0.9 
0.2 
0.5-1.1
1.1 
0.2 
0.9-1.3
160
40
110-221
0.2 
0.04 
0.1-0.3
Middle
aged
mean
s.d.
range
0.8 
0.3 
0.3-1.3
0.8 
0.2 
0.6-1.2
188
57
147-337
0.2 
0.06 
0.1-0.3
Elderly
mean
s.d.
range
0.6 
0.1 
0.3-0.9
0.8 
0.1 
0.6-0.9
177
34
144-225
0.1 
0.03 
0.1-0.2
AUC„ Area under metabolite time/concentration curve,
M
AUCd Area under drug time/concentration curve.
BetaT1^2 Elimination half life.
Vd Volume of distribution at steady state.
ub
TABLE 18: Trimazosin pharmacokinetic parameters
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Figure 10: Age and the clearance of
trimazosin. Linear regression analysis.
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Figure 11: Relationship between age and
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trimazosin and hydroxytrimazosin 
time-concentration curves. Linear 
regression analysis.
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Examination of the mean blood pressure profiles 
demonstrated a significantly greater effect in the elderly 
subjects than in the middle aged and young (P < 0.05), 
Figure 12. A biphasic response was shown in all subjects 
by the concentration effect model. The first response 
being due to the drug and the second to the active 
metabolite. The mean effect model parameters are given in 
Table 19 and Table 20. There were no significant effects 
of age upon the sensitivity to trimazosin expressed in 
terms of placebo corrected fall in erect systolic blood 
pressure per unit of drug concentration. There were no 
significant effects of age upon Keq, the first order rate 
constant describing the disequilibrium between 
concentration and effect. (Effectively this reflects the 
time lag between the plasma concentration and the 
corresponding lowering of blood pressure.) Similarly 
there was no relationship between the sensitivity to the 
drug and age when linear regression analysis was applied.
The greater response to trimazosin observed in the elderly 
can be attributed to the decline in drug clearance with 
age. The sensitivity to this alpha-l-adrenoceptor 
antagonist did not change with age.
Acebutolol
The pharmacokinetic parameters for acebutolol are shown in 
Table 21. There were no significant differences between; 
clearance, elimination half-life, volume of distribution 
or the ratio of the area under the drug and metabolite 
concentration curves (relative metabolite clearance).
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Figure 12: Mean change in systolic blood
pressure and pulse rate in response to 
intravenous trimazosin: young, middle aged 
and elderly volunteers.
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Responsiveness
-1 -1 (mmHg.ng .ml )
Drug Metabolite
mean 1.5 3.1
Young s.d. 0.6 1.0
range 0.9-2.3 2.0-5.1
mean 1.7 3 . 3
Middle s.d. 0.6 0.7
aged range 0.7-2.3 2.5-4.6
mean 1.7 3 . 6
Elderly s.d. 0.6 0.8
range 0.9-2.8 2.5-3.6
TABLE 19: Trimazosin responsiveness (placebo corrected
fall in erect systolic blood pressure per unit plasma 
drug/metabolite concentration.
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ke<I _1 
(l.min )
Drug Metabolite
mean 0.10 0.01
Young s.d. 0.01 0. 004
range 2.00-0.11 0.008-0.015
mean 0.10 0.01
Middle s.d. 0. 01 0. 004
aged range 0.08-0.11 0.008-0.014
mean 0. 09 0. 01
Elderly s.d. 0. 01 0. 004
range 0.08-0.11 0.008-0.013
TABLE 20: Trimazosin "keq" - A measurement of the
discrepancy between the plasma concentration and the 
hypotensive effect of the drug.
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Clearance A U c y  BetaT1/2 Vdss
D (min) (1/kg)
Young
mean
s.d.
range
387
168
192-653
0.5 
0.2 
0.3-0.6
184
63
115-307
1.3 
0.3 
0.9-1.6
Middle
aged
mean
s.d.
range
393
122
158-592
0.6 
0.4 
0.3-1.5
175
52
119-293
1.2 
0.56 
0.7-2.2
Elderly
mean
s.d.
range
402
132
265-638
0.5
0.2
0.04-0.9
175
74
93-351
1.2 
0.3 
0.8-1.7
AUC„ Area under metabolite time/concentration curve,
M
AUCd Area under drug time/concentration curve.
BetaT1^2 Elimination half life.
Vd Volume of distribution at steady state.
SS
TABLE 21: Acebutolol pharmacokinetic parameters
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Linear regression analysis also failed to demonstrate any 
effect of age on these parameters.
Conventional analysis of blood pressure and heart rate 
profiles revealed no significant effects of age when 
comparisons are made between the groups. Significant 
falls in blood pressure were seen in all three groups.
The mean effect model parameters are given in Table 22. 
there were no significant differences between the groups 
as assessed by analysis of variance. However, linear 
regression analysis demonstrated that there was a 
significant negative correlation between sensitivity (unit 
fall in placebo corrected erect systolic blood pressure 
per unit of drug concentration) and age (P < 0.005; 
r = -0.51) Figure 13. Regression analysis failed to 
demonstrate any other significant effects of age on Keq 
which describes the disequilibrium between concentration 
and effect.
Tolmesoxide
The pharmacokinetic parameters are shown in Table 23.
There were no significant differences between the groups 
in any of the parameters, nor were there any with linear 
regression analysis.
Tolmesoxide produced significant changes in blood pressure 
and heart rate in all three groups. The mean effect model 
parameters are shown in Table 24. There was no 
significant effect of age upon the responsiveness of
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Responsiveness
-1 -i
(mmHg.ng .ml )
keq 
(l.min 1)
mean 0.2 0. 009
Young s.d. 0.1 0. 001
range 0.1-0.3 0.008-0.01
mean 0.1 0. 009
Middle s.d. 0. 04 0.001
aged range 0.1-0.2 0.007-0.01
mean 0.1 0.009
Elderly s.d. 0. 03 0. 002
range 0.1-0.2 0.007-0.01
TABLE 22: Acebutolol - Concentration effect
modelling parameters: Responsiveness and keq 
(a measure of the discrepancy between the 
plasma concentration and hypotensive effect
125
re
sp
on
si
ve
ne
ss
 
(m
m 
H
g
/n
g
/m
l) 0.3
r- -0.61 (p<0.005)
0.25
■ ■
0.2
■ ■0.15
0.1
0.05
20 30 40 50 60 70 80
age (yrs )
Figure 13: Relationship between the
sensitivity to acebutolol (unit fall in 
placebo corrected systolic blood pressure 
per unit of drug concentration) and age.
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Clearance AUV
a u c d
B0taTl/2
(min)
vdss
(l.kg”1)
Young
mean
s.d.
range
6.0 
3.7 
2.3-11.0
0.7 
0.2 
0.5-1.5
290
67
97-307
2.3 
0.5 
1.0-2.7
Middle
aged
mean
s.d.
range
4.2
1.2
2.0-5.1
0.5 
0.1 
0.3-0.8
175
45
104-236
1.0 
0.36 
0.7-1.4
Elderly
mean
s.d.
range
4.5 
1.4 
2.9-6.5
0.6 
0.1 
0.4-1.0
182
46
124-172
1.1 
0.3 
0.8-1.7
AUC„ Area under metabolite time/concentration curve. M
AUCD Area under drug time/concentration curve. 
BetaT1^2 Elimination half life.
Vdcc Volume of distribution at steady state.
b u
TABLE 23: Tolmesoxide pharmacokinetic parameters
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Responsiveness
-1 -1 (mmHg.ng .ml )
keq 
(l.min 1)
Young
mean
s.d.
range
12.6 
2.1 
9.8-15.6
0.02
0.01
0.01-0.02
Middle
aged
mean
s.d.
range
10. 8 
1.7 
8.6-13.0
0.02
0.021
0.01-0.02
Elderly
mean
s.d.
range
11.3
2.1
8.7-13.4
0.02
0.01
0.01-0.03
TABLE 24: Tolmesoxide - Concentration effect
modelling parameters: Responsiveness and keq 
(a measure of the discrepancy between the 
plasma concentration and hypotensive effect
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tolmesoxide in terms of placebo corrected fall in erect 
systolic blood pressure per unit of drug concentration. 
There was also no difference in the Keq values. Once 
again linear regression analysis failed to show any 
differences when age was treated as a continuous spectrum.
5.4 DISCUSSION
This study demonstrated that, with increasing age, in 
normal volunteers, the hypotensive effect of trimazosin 
was increased, that of acebutolol was decreased, while 
there was no change in the response to tolmesoxide. The 
increased hypotensive action of trimazosin in the elderly 
was due to reduced clearance; the blood pressure fall per 
unit drug concentration remained unchanged. The reduced 
effect of acebutolol in the elderly was due to decreased 
drug sensitivity; drug clearance remaining unchanged. 
Tolmesoxide clearance and effect were both unaltered by 
age.
Drug sensitivity
The unchanged sensitivity to trimazosin adds to the 
evidence that the activity of the alpha-l-adrenoceptor 
remains unaffected by age (Chapter 2). However, the 
influence of age on baroreceptor reflexes could not be 
controlled in this study. It is therefore not possible to 
make firm conclusions about adrenoceptor sensitivity. The 
same difficulty exists in the interpretation of other 
similar i n  v i v o  studies. Two studies have been carried
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out examined the effect of age on the responses to the 
alpha-l-adrenoceptor agonist phenylephrine and antagonist 
prazosin in groups of normal volunteers (106,107).
Elliott et al (106) produced evidence for a slight fall in 
receptor sensitivity with age, but Klein et al (107) 
demonstrated no change in receptor sensitivity with age.
In a recent study of the concentration-effect of the 
alphal-adrenoceptor antagonist, doxazosin, there was no 
change in the sensitivity of the receptor with age (152). 
Overall this study supports the larger body of evidence 
that there is no change in the sensitivity of the 
alpha-l-adrenoceptor with age (Chapter 2).
The relative resistance of the older volunteers to the 
beta-l-adrenoceptor antagonism of acebutolol gives support 
to the hypothesis that the effect of the cardiac 
beta-l-adrenoceptor is reduced in the elderly (Review: 
51,52,153). This is in agreement with Vestal et al. (84) 
who demonstrated that the elderly are less sensitive to 
the cardiac effects of the non selective beta-adrenoceptor 
agonist (isoprenaline) and antagonist (propranolol). 
However, a more recent study confirmed that while the 
elderly had less cardiac acceleration with isoprenaline, 
the sensitivity to the non-selective beta-adrenoceptor 
antagonist timolol was unchanged (154). The apparent 
conflict in the results of these two studies may be the 
result of differences in the proportion of free active 
drug available as compared to the inactive protein-bound 
drug. Propranolol, as a basic drug, is highly bound to 
alpha-l-acid glycoprotein, an acute phase protein whose
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concentration is known to increase with disease and is 
therefore commonly present at higher plasma concentrations 
in the elderly (56). In contrast timolol is minimally 
bound to plasma proteins.
There appears to be no substantial change in the number of 
lymphocyte beta-adrenoceptors with increasing age 
(155,156) but there is evidence for a reduction in 
receptor affinity (157). The effect of age on the 
stimulation of lymphocyte adenylate cyclase by 
beta-adrenoceptor agonists has been shown to be unchanged 
(158) or reduced (159) in the elderly. There is also an 
age related reduction in the stimulation of adenylate 
cyclase activity by prostaglandin (160) and by sodium 
fluoride (161). In summary, the evidence from studies of 
lymphocyte beta-adrenoceptors points to reduced receptor 
affinity and to reduced activity of adenylate cyclase, but 
the relevance of these results to innervated 
cardiovascular tissue remains questionable.
The evidence concerning the activity of the beta-2- 
adrenoceptor and ageing is conflicting.
Beta-2-adrenoceptor mediated vasodilatation to 
intra-arterially injected isoprenaline decreases with age 
(162). Similarly there is a decrease in the dilatation of 
the dorsal hand vein to isoprenaline with age (110). 
However, using plethysmography, there was no age related 
change in vasodilatation in the calf in response to an 
intravenous infusion of adrenaline (163). Furthermore, 
the respiratory and metabolic effects of
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beta—2—adrenoceptor stimulation does not appear to change 
with age (36,164). The number of beta-2-adrenoceptors 
present on human rectus abdominis muscle biopsies has been 
estimated by ligand binding and does not change with age 
(165).
Overall the evidence points to a reduction in the activity 
of the elderly beta-l-adrenoceptor which may be due to a 
small reduction in affinity but more significantly to 
changes in the post-receptor chain of events. Further 
study is still required on the effect of age on both the 
beta-1 and beta-2-adrenoceptors.
The sensitivity of the elderly to tolmesoxide is unchanged 
with increasing age. Tolmesoxide acts directly on 
vascular smooth muscle to produce vasodilation. There is 
very little information available concerning the effect of 
age on the activity of such vasodilators. In the dorsal 
hand vein, where dilatation to isoprenaline was 
diminished, there was no evidence for change in the 
venodilatation produced by nitroglycerin (110). There is 
some evidence that the hypotensive response to the calcium 
channel blocker, nifedipine, is greater in the elderly 
(130), although overall there is probably little effect of
age (166). In general, although there is very little
clinical experimental data, this study is in agreement
with there being no age related change in the sensitivity
of vascular smooth muscle to dilator drugs which act 
independently of adrenoceptors.
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Pharmacokinetic changes with aae
There are 3 other studies on the effect of age on the 
pharmacokinetics of quinazoline alpha—adrenoceptor 
antagonists. Two of these studies included intravenous 
drug administration, of prazosin (Chapter 3) and doxazosin 
(167). With increasing age, prazosin had an increase in 
volume of distribution but no change in clearance (Chapter 
3) . With doxazosin, there was greater variability in the 
drug kinetic measurements in the old, but there was a 
significant increase in the volume of distribution and 
this was associated with an increase in clearance. In a 
study of orally administered prazosin and terazosin 
involving normal volunteers (young 19-30 years and 'old' 
54-62 years) (142) there was no change in the area under 
the time-concentration curve or in the elimination 
half-life of prazosin. With terazosin, there was an 
increase in both the area under the time-concentration 
curve and elimination half-life in the older subjects.
The present study does not show any effect of age on 
acebutolol metabolism and elimination. This confirms a 
previous study (168), however an earlier report suggested 
that the elimination half-life of acebutolol was prolonged 
in the elderly when given by the oral but not intravenous 
route (169). The major metabolite, diacetolol, has been 
reported to have beta-adrenoceptor antagonist properties 
(170). Using the concentration- effect model, the present 
study provides no evidence that diacetolol contributed to 
the hypotensive effect.
133
There are no other studies on the effect of age on the 
pharmacokinetics of tolmesoxide.
Study design
This study illustrates the benefit of using a continuous 
age spectrum in an examination of the effect of age in 
clinical pharmacology. Analysis of data arbitrarily 
divided into age groups did not demonstrate significant 
differences which only became apparent when all subjects 
were analysed together by linear regression. Once again 
this study demonstrates the importance of intravenous drug 
administration for the calculation of volume of 
distribution and drug clearance.
In 30 normotensive volunteers, there was a reduction in 
the clearance of trimazosin and no change in the clearance 
of acebutolol or tolmesoxide with age. Using 
concentration-effect analysis, it has been shown that the 
sensitivity to acebutolol decreases with age while that to 
trimazosin and tolmesoxide remain unchanged.
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CHAPTER 6
DOUBLE BLIND CROSS-OVER COMPARISON OF DOXAZOSIN AND 
PLACEBO IN ELDERLY HYPERTENSIVE PATIENTS
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DOUBLE BLIND CROSS-OVER COMPARISON OF DOXAZOSIN AND 
PLACEBO IN ELDERLY HYPERTENSIVE PATIENTS
6.1 INTRODUCTION
Doxazosin is a quinazoline derivative with selective 
alpha-l-adrenoceptor blocking activity comparable to the 
related drug, prazosin (171), but with a more gradual 
onset of hypotensive activity (172). Combined 
pharmacokinetic and dynamic studies in young and elderly 
volunteers have indicated that doxazosin has a duration of 
action suggesting the potential for once daily dosing 
(167,152). The efficacy of once daily doxazosin in the 
treatment of essential hypertension has previously been 
demonstrated in younger patients (173,174).
This study was designed to investigate the efficacy and 
safety of once daily doxazosin in elderly hypertensive 
patients living in the community. The pharmacokinetic 
profile was also investigated after steady-state oral 
dosing.
6.2 METHOD 
Patient selection
Patients aged 65 and over who had mild to moderate 
hypertension, with diastolic blood pressures of 95 to 120 
mmHg took part. All lived at home. Patients with angina
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pectoris requiring treatment, cardiac failure not 
controlled by diuretics or other major concurrent diseases 
were excluded. Concomitant treatment with diuretics was 
allowed, provided the dose remained unchanged throughout 
the study, but treatment with other antihypertensive drugs 
was not allowed during the study or for 4 weeks before 
entering the placebo run-in period.
Study design
The study was a two centre, double-blind, randomized, 
cross-over comparison of once daily doxazosin and placebo, 
preceded by a 4 week single-blind placebo run-in period.
At the end of the run-in period patients with a diastolic 
blood pressure greater or equal to 95 mmHg both supine and 
standing were randomized to treatment with doxazosin or 
placebo for 10 weeks. At the end of this period the 
patients were given the alternative treatment for a 
further 10 weeks.
Treatment was given once daily in the morning. The dose 
was titrated at two-weekly intervals by using double-blind 
identically matching tablets of doxazosin and placebo. 
During the doxazosin period the initial dose was 1 mg and 
subsequently daily doses were 2 mg, 4 mg, 8 mg and 16 mg.
The patients were reviewed at two-weekly intervals 
throughout the study. They were told to take their 
tablets 24 hours before the review visits and to record 
the time on a diary card. On the day of the review they 
did not take their medication until after the blood
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pressure measurements had been made. Compliance with drug 
therapy was checked at every visit with a tablet count.
The target antihypertensive effect was defined as a 
reduction in both supine and standing blood pressures to 
below 95 mmHg and by at least 10 mmHg measured 24 hours 
after the dose.
Clinical measurements
At each review visit resting blood pressure and radial 
pulse were measured in duplicate after 5 minutes in the 
supine position and after 2 minutes standing. Blood 
pressure was measured using a random zero sphygmomanometer 
(Hawksley) and Phase V diastolic blood pressure was 
recorded.
A 12-lead ECG was recorded on entry to the study, at the 
end of the placebo run-in period and at the end of each 
treatment period.
All volunteered or observed adverse events were recorded 
at each review visit. Haematological and biochemical 
screens and routine urinalysis were performed on entry 
into the study, at the end of the run-in period and during 
and at the end of each treatment period (weeks 8, 14, 18 
and 24). Body weight was recorded with electronic digital 
scales (Siemans) at each visit.
Steady State Pharmacokinetics
All patients who completed both phases of double-blind
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treatment were eligible for entry into the pharmacokinetic 
study. Those who completed the double blind study on 
doxazosin were continued on the same dose in an open 
manner.
The placebo treated patients were retitrated to the 
doxazosin dose reached during the first period of the 
cross—over or to that dose which controlled blood pressure 
(as defined above) if this was lower. All patients were 
maintained at constant dose of doxazosin for at least 14 
days before pharmacokinetic assessment. During the 
pharmacokinetic study blood samples were taken immediately 
before administration of a supervised dose of doxazosin 
and at 1 ,2, 3, 4, 6, 8, 12, 24 and 48 hours after the 
dose.
Plasma doxazosin analysis
The plasma was separated by centrifugation and stored at
-2 0°C until assayed for doxazosin. Samples were analysed
by high performance liquid chromatography using
fluorescence detection with prazosin as the internal
standard (175). All samples were analysed in duplicate
and calibration standards and quality controls were
processed in the same way as unknowns. The lower limit of
—1 .detection was 1 ng.ml . The precision of the method of 
analysis (n = 4-10) expressed as the coefficient of 
variation was +9.6, +2.9, +3.5 and +6.8 at 1, 10, 40 and 
100 ng.ml”1 respectively. Areas under the doxazosin 
plasma concentration-time curves were calculated by the 
linear trapezoid rule and regression lines were fitted by
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least squares regression analysis. The plasma elimination 
half-lives within the dosage interval were calculated by 
applying a one compartment model with duration times of 
the observed terminal linear phase from 4 or 6 hours to 24 
hours.
Statistical Analysis
For blood pressure and heart rate the results are 
expressed as mean values with 95% confidence intervals of 
the mean changes. Analysis of variance (with treatment, 
period of study and patient as factors) was carried out in 
order to assess treatment differences in (final-baseline) 
changes. P values for comparisons of blood pressure and 
heart rate changes are based on two-sided tests.
6.3 RESULTS 
Patients
Forty Caucasian patients (16 men, 24 women) aged 65 to 82 
years (mean 71.4 years) entered the double blind period,
21 being randomized to treatment with doxazosin during the 
first phase and 19 to placebo, The mean duration of 
diagnosed hypertension was 5.3 years (range 1 month to 20 
years). Twenty one patients received other medication 
during the double-blind doxazosin phase of the study and 
20 patients during the double-blind placebo phase 
(Table 25). Twenty-eight patients completed both phases 
of double-blind therapy.
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Drug Number of
patients
Analgesics 7
Antacids 1
Antibacterials 11
Cyanocobalamin 1
Decongestants 2
Diuretics 7
Fenfluramine 1
Glibenclamide 1
Inositol nicotinate 1
Mianserin 1
Multivitamins 1
Nonsteroidal anti-inflammatory 9
Quinine sulphate 2
Salbutamol 1
Temazepam 2
Thyroxine 1
TABLE 25: Other drugs taken during the study.
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Six patients were withdrawn from the study during 
doxazosin treatment and 6 during double-blind placebo 
treatment. The reasons for withdrawal during doxazosin 
treatment were: two patients developed intercurrent 
illnessess (multiple metastases and uncontrolled 
non-insulin dependent diabetes), one patient died, one 
patient experienced minor adverse effects and two patients 
moved away from the area of the study. The reasons for 
withdrawal during placebo treatment were: two patients 
suffered intercurrent illnesses (congestive cardiac 
failure, and hospital admission for prostatectomy), one 
patient moved from the area, two patients showed poor 
compliance (repeatedly forgetting to take the tablets) 
with therapy and one patient was withdrawn due to lack of 
efficacy.
Another two patients were excluded from the efficacy 
analysis, as both had a diuretic added to treatment during 
the double-blind phase of the study. Twenty six patients 
were therefore included in the efficacy analysis. The 
mean final daily dose of doxazosin in these patients was 
8.6 mg (range 1-16 mg) and the mean durations of therapy 
for doxazosin and placebo treatment were 71.5 days (range 
63-92) and 72.6 days (range 64-95) respectively. The 
distribution of doxazosin doses before final assessment 
for this group of patients is shown in Table 26.
Blood Pressure and Heart Rate
Blood pressure and heart rate measurements 24 hours after 
the dose at the end of each period of double blind
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Dose
(mg/day)
Number of
patients
1 2
2 3
4 6
8 6
16 9
TABLE 26: Doxazosin dose before the final blood
measurement in those patients analysed for 
efficacy.
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treatment were compared with baseline values, which were 
taken as the mean of the measurements made at the end of 
Weeks 2 and 4 in the placebo run-in period. The mean 
baseline, mean final and mean changes (final-baseline) in 
blood pressures and heart rates are shown in Table 27 and 
Table 28.
The mean changes from baseline in standing blood pressures
(mmHg) were -12.7/-12.5 (systolic/diastolic) for doxazosin
and -5.7/-6.9 for placebo. The corresponding mean changes
in supine blood pressure were -6.1/-10.3 for doxazosin and
+0.2/-4.8 for placebo (Figure 14). The mean reductions
from baseline both in standing and supine diastolic blood
pressures were significantly greater at the end of
doxazosin treatment (p < 0.05). The reductions in
standing and supine systolic blood pressures were not
statistically significant when compared with placebo.
There were rises in both standing and supine heart rates
. -1with doxazosin (3.2 and 1.7 beats.mm ) compared with
. - i
falls with placebo (-0.1 and -2.1 beats.mm ), but these 
changes were not statistically significant.
Pharmacokinetics
Eighteen patients (6 men, 12 women) aged 65 to 82 years 
(mean 71.4 years) entered the pharmacokinetic study. The 
blood pressure profile over the pharmacokinetic study 
period (24 hours) is shown in Figure 15. The mean duration 
of continuous doxazosin therapy before pharmacokinetic 
analysis was 80.7 days (range 22 to 146 days). The 
distribution of doxazosin dose and mean
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Baseline Placebo
Final
mean
Mean 
change 
(95% conf)
ERECT POSITION
Systolic (mmHg) 178.5 172 .8 -5.7
(-12.4,1.6)
Diastolic (mmHg) 108.4 101.5 -6.9 
(-10.1,-3.5)
Pulse (beats/min) 81.5 81.5 -0.1 
(-3.0,+2.5)
SUPINE POSITION
Systolic (mmHg) 181.4 181. 6 +0.2 
(-5.9,+6.1)
Diastolic (mmHg) 105.4 100. 6 -4.8 
(-7.5,-2.2)
Pulse (beats/min) 78.6 76.4 -2.1 
(-6.3,+1.1)
TABLE 27: Changes in pulse and blood pressure
following placebo therapy.
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Baseline Doxazosin Doxazosin
mean ----------------  Placebo
Final Mean Difference
mean change (95% conf) 
(95% conf)
ERECT POSITION
Systolic (mmHg) 178.5 165.8 -12.7 
(-20.0,-6 .0)
-6.9 
(-17.4,+2.2)
Diastolic (mmHg) 108.4 95.9 -12.5 
(-15.9,-9 .4)
*
-5.6 
(-10.4,-1.3)
Pulse (beats/min) 81.5 84.7 +3.2 
(+0.7,+6 •1)
+3.2 
(-0.8,+7.4)
SUPINE POSITION
Systolic (mmHg) 181.4 175.3 -6.1 
(-12.0,0. 0)
-6.2 
(-14.5,+2.3)
Diastolic (mmHg) 105.4 95.1 -10.3 
(-12.9,-7 .6)
*
-5.5 
(-9.1,-1.8)
Pulse (beats/min) 78. 6 80.2 +1.7 
(-1.6,+5 .9)
+3.7 
(-0.4,+10.0)
* p < 0.05 for doxazosin-placebo difference 
in final baseline changes.
TABLE 28: Changes in pulse and blood pressure
following doxazosin.
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pharmacokinetic variables are shown in Table 29. Both the 
time to peak plasma concentration and the plasma 
elimination half-life were independent of dose, with a 
median time to peak plasma concentration for all patients 
of 3 hours (range 1-4 hours) and a mean plasma elimination 
half-life (n = 17) within the dose interval of 16.1 hours 
(range 10.1 - 27.1 hours). One patient was excluded from 
the analysis of terminal elimination half-life because 
there was a poor fit to the calibration curve. Within the 
dosage range 1 to 16 mg, the peak plasma concentration 
during the dosage interval and the average concentration 
during the dosage interval (AUC(0-24)/24) were linearly 
related to dose (Figure 16).
Adverse Events
All the patients who entered double-blind treatment were 
evaluated for adverse events. Nine patients reported 
unwanted effects during doxazosin treatment and five 
during double-blind placebo treatment. One patient taking 
doxazosin (1 mg) reported headache, increased sweating and 
weakness and was withdrawn from the study. Dizzyness was 
the most frequently reported unwanted effect; it was 
reported in 5 patients during doxazosin treatment and four 
patients during placebo treatment. Dizziness in these 
patients disappeared with continued treatment, one 
doxazosin-treated (4 mg) patient receiving a reduced dose. 
The remaining drug-related (or possibly drug-related) 
adverse effects headache, dyspnoea, lethargy, nausea and 
ankle oedema during doxazosin treatment and nausea during 
placebo treatment, were minor and were generally tolerated
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Doxazosin dose (mg/day) A11A
Pat­
1 2 4 8 16
ients
Number 3 4 2 5 4 18
Terminal 
elimination 
half-life (h)
14.4
±1.7
15.7
±3.0
18.1
c
16.2
±7.5
16.9
±6.7
16.1C 
±5.0
Time to 
peak (h)
2 . 0 
(2-4)
2.5
(1-3)
1.5 3 . 0 
(2-3)
3.5
(2-4
3.0
(1-4)
Peak
concentrat­
ion (ng/ml)
9.4
±1.5
18.0
±3.2
28.7 84 .7 
±10. 6
168
±45.2
9.6
±2.0
Minimum 3.2 
concentrat- +1.0 
ion (ng/ml)
(24hr post dose)
6.7
±1.3
11.0 26.9
±3.5
57.8
±26.9
3.3
±1.0
AUC(0-24)/24 
(ng/ml)
5.6 
±1.4
11. 2 
±1. 4
17.2 46.5
±4.2
97
±29.1
5.6
±1.1
A The values for peak concentration, minimum conc- 
concentration, and AUC(0-24)/24 are normalized 
to a lmg dose.
B The values for time to peak concentration are 
given as medians and ranges.
C One patient was excluded from the analysis of 
terminal half-life because there was a poor fit 
to the calibration curve.
TABLE 29: Summary of pharmacokinetic data of
doxazosin (mean with s.d.)
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Figure 16: Relationship between dose of
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or disappeared with continued therapy.
One previously untreated hypertensive man died from a 
suspected stroke while taking doxazosin (2 mg). 
Satisfactory blood pressure control in this patient had 
not been achieved.
There were no statistically significant difference in mean 
changes in body weight at the end of 10 weeks treatment 
with doxazosin or placebo.
No patterns of changes were observed in either treatment 
group with respect to haematological or biochemical 
measurements. The incidence of abnormalities was similar 
in both treatment groups (13 for doxazosin and 14 for 
placebo) and the range of abnormalities were also similar. 
There was no evidence of drug- related changes in ECG in 
either treatment group.
6.4 DISCUSSION
Choice of antihvoertensive therapy for the elderly 
The prevalence of hypertension in the elderly is very high 
and rises with age (43); in the Framingham study high 
blood pressure has been identified in approximately 40% of 
males and 50% of females between the ages of 65 and 94 
years. Hypertension in elderly patients is associated 
with blunted beta-adrenoceptor mediated effects; exercise 
induced tachycardia and heart rate responses to
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isoprenaline are reduced (108), plasma renin activity is 
normal or low (176,177), there is a hyper- reponsiveness 
to sympathetic stimuli (45) and peripheral vasodilator 
responses to beta-adrenoceptor stimulation are diminished 
(162). In contrast to the beta-adrenoceptor the activity 
of the vasoconstrictor alpha-l-adrenoceptor, which appears 
to be unchanged in the normotensive elderly (Chapter 3), 
may even be enhanced in the older hypertensive patient 
(178). These observations give rise to the suggestion 
that peripheral vasodilator drugs, for example, 
alpha-l-adrenoceptor antagonists, may have a primary role 
to play in the treatment of hypertension in the elderly 
where peripheral resistance is high (58).
The reduction in baroreceptor activity seen with age (1) 
contributes to the increased risk of drug induced postural 
hypotension seen in the elderly (4). Prazosin may cause 
severe postural hypotension with the first dose (179). It 
also has a short elimination half-life in young and 
elderly (Chapter 4) and has to be administered twice or 
three times a day. Prazosin is therefore not an ideal 
drug for the treatment of the elderly hypertensive.
Doxazosin and the elderly hypertensive patient 
This study examined the effect of doxazosin in elderly 
hypertensive patients. Doxazosin and prazosin are both 
quinazoline derivatives, but doxazosin had been shown to 
have a longer elimination half-life in both young (167) 
and elderly (167) normal volunteers.
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Forty patients entered this double-blind placebo 
controlled cross-over study. Twenty eight completed both 
phases of double blind treatment but due to the addition 
of diuretic therapy, two further patients were excluded 
from the examination of drug efficacy. Doxazosin produced 
a significant, but small, fall in placebo corrected 
diastolic blood pressure 24 hours post dosing, (-6.9 mmHg 
erect, -6.2 mmHg supine). There was no significant fall 
in systolic pressure when compared to placebo. The 
hypotensive efficacy of doxazosin has also been described 
in a multicentre study involving 903 patients (181). 
Doxazosin was compared with placebo in a subgroup of 172 
young and old patients. Recalculation of the published 
data from this trial confirms the modest effect of 
doxazosin on placebo corrected diastolic pressure 
(-7.7 mmHg erect, -4.7 mmHg supine).
One patient was withdrawn from the present study due to 
adverse effects during doxazosin treatment. The other 
adverse effects were minor and were well tolerated, or 
dissapeared with continued therapy. The most frequently 
reported side effect was dizziness, which occurred in a 
similar proportion of doxazosin and placebo treated 
patients.
One patient died from a suspected stroke during doxazosin 
therapy. His hypertension had not been previously treated 
and control had not been achieved with doxazosin therapy.
Assessment of steady-state pharmacokinetics was carried
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out in 18 of these patients. Over the dosage range 1-16 
mg/day plasma concentrations were linearly related to 
dose, suggesting that absorption of doxazosin in the 
elderly is not dose-dependent. Peak plasma concentrations 
occured 1 to 4 hours after dosing. The mean plasma 
elimination half-life was 16.1 hours (range 10.1 - 27.1 
hours), which is longer than the 8.8 ± 4.2 hours reported 
in an acute dosing study (180). This supports the 
observation that the elimination half life of doxazosin is 
prolonged with chronic dosing (152).
The modest fall in diastolic blood pressure, 24 hours post 
dose, and the lack of signficant effect on systolic 
pressure shown in this study suggests that doxazosin is 
unlikely to play a major role in the treatment of 
hypertension in the elderly.
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CONCLUSION
The studies described in this thesis examine aspects of 
the effects of ageing on the physiology and pharmacology 
of the sympathetic nervous system.
The examination of noradrenaline disposition in age was 
the first to report the increased spillover of the neuro­
transmitter in the elderly. Subsequent studies have all 
confirmed this finding.
The study on human isolated arteries was the first to 
report the lack of change in the sensitivity of the 
alpha-l-adrenoceptor with age. All subsequent studies 
have confirmed this finding.
The study on prazosin disposition and ageing demonstrated 
that there was a reduction in the bioavailability and an 
increase in the volume of distribution. These changes are 
unlikely to be of clinical significance.
The effect of age was described on the hypotensive action 
and metabolic fate of trimazosin, acebutolol and 
tolmesoxide. The clearance of trimazosin was reduced but 
that of acebutolol and tolmesoxide remained unchanged.
The hypotensive action of acebutolol was reduced with age 
while that of trimazosin and tolmesoxide was unchanged.
Doxazosin, given once and day, produced a modest fall in
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diastolic pressure in a group of elderly hypertensive 
patients. There was no significant fall in systolic blood 
pressure.
Research into the physiology and pharmacology of ageing is 
becoming increasingly important. Within a very few 
decades, there will be considerable increases in the 
numbers of elderly in almost all developed countries. The 
work described in this thesis was carried out over a ten 
year period and the studies reflect changes in 
experimental design over that period.
It is now necessary to study each new drug in elderly 
volunteers and patients. It is better to examine age as a 
continuous variable rather than studying two groups of 
young and elderly. In Clinical Pharmacology, it is not 
acceptable to calculate clearance of a drug from oral 
dosing studies.
I would hope that an increased understanding of aging and 
its effect of therapy will help to reduce the current 
epidemic of adverse drug reactions seen in our elderly 
patients.
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